



**Mortality and its determinants among HIV-1 infected patients on antiretroviral therapy in a referral centre in Yaounde, Cameroon: a retrospective cohort study**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-003210
Article Type:	Research
Date Submitted by the Author:	11-May-2013
Complete List of Authors:	Poka, Virginie; Yaounde Jamot Hospital, Pneumology Service Pefura-Yone, Eric Walter; Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Department of Internal Medicine and Subspecialties Kengne, Andre; South African Medical Research Council, Kuaban, Christopher; Faculty of Health Sciences, University of Bamenda, ; Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Department of Internal Medicine and Subspecialties
<b>Primary Subject Heading</b>:	HIV/AIDS
Secondary Subject Heading:	Infectious diseases
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, Epidemiology < INFECTIOUS DISEASES, EPIDEMIOLOGY

SCHOLARONE™  
Manuscripts

only

1 **Mortality and its determinants among HIV-1 infected patients on antiretroviral therapy in a**  
2 **referral centre in Yaounde, Cameroon: a retrospective cohort study**  
3  
4

5 **Short title: Determinants of death among patients with HIV infection**  
6  
7

8 Virginie POKA-MAYAP (1), Eric Walter PEFURA-YONE (1, 2), André Pascal KENGNE (3),  
9 Christopher KUABAN (1, 2)  
10

- 11  
12 1) Pneumology Service, Yaounde Jamot Hospital, Cameroon  
13  
14 2) Department of Internal Medicine and Subspecialties, Faculty of Medicine and Biomedical  
15 Sciences, University of Yaounde I, Cameroon  
16  
17 3) South African Medical Research Council & University of Cape Town, Cape Town, South  
18 Africa  
19  
20 4) Faculty of Health Sciences, University of Bamenda, Cameroon  
21  
22  
23  
24

25 **Correspondence to:**  
26

27 Dr Virginie Poka-Mayap,  
28  
29 Yaounde Jamot Hospital,  
30  
31 PO Box 4021-Yaounde, Cameroon  
32  
33  
34 Tel: (237)99253759,  
35  
36  
37 Email: pokavirginie@yahoo;fr  
38  
39

40 **Tables: 2**  
41

42 **Figures: 0**  
43

44 **Online only material: 0**  
45

46 **Word count:** abstract-267; Main text (excluding tables, figures, abstract & references)-2664  
47  
48

49 **References: 18**  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**ABSTRACT**

**Objectives:** Mortality has decreased in people with human immunodeficiency virus (HIV) infection, subsequent to the improved access to antiretroviral therapy (ART). We assessed the incidence and determinants of fatal outcomes among patients with HIV-1 infection, started on ART in a referral treatment centre for HIV infection in Yaounde, Cameroon.

**Design:** Cohort study with baseline assessment between 2007 and 2008, and follow-up until June 2012.

**Setting:** The approved centre for HIV treatment of the Yaounde Jamot, in capital city of Cameroon.

**Participants:** Patients with HIV infection who were started ART between 2007 and 2008 at the study centre.

**Outcome measures:** All-cause mortality over time, with the accelerated failure time models were used to relate baseline characteristics with mortality occurrence during follow-up.

**Results:** Of the 1444 patients included, 827 (53.7%) were men, and median age (25<sup>th</sup>-75<sup>th</sup> percentiles) was 38 (31-45) years. The median duration of follow-up was 14.1 (1.1-46.4) months, during which 235 deaths were recorded (cumulative incidence rate: 16.3%), including 208 (88.5%) during the first year of follow-up. Baseline predictors of mortality were male gender [adjusted hazard ratio 2.15 (95%CI: 1.34-3.45)], active tuberculosis [2.35 (1.40-3.92)], WHO stages III-IV of the disease [3.63 (1.29-10.24)], low weight [1.03 (1.01-1.05) per kilogramme], low CD4 count [1.04 (1.01-1.07) per 10/mm<sup>3</sup>] and low haemoglobin levels [1.12 (1.00-1.26) per g/dl].

**Conclusions:** Death rate among patients with HIV is very high within the first year of starting ART in this centre. Early start of the treatment, at a less advanced stage of the disease, and much favourable levels of CD4 and other predictors may improve the outcomes of patients, but would have to be tested.

*Word count – 267*

*Key words:* HIV infection, death, determinants, cohort

## ARTICLE SUMMARY

### Article focus

- To investigate mortality occurrence and determinants among patients with HIV-1 infection, started on antiretroviral therapy in a major reference treatment centre

### Key messages

- Death rate among patients with HIV is very high within the first year of starting ART in this centre
- Male gender, active tuberculosis, advanced stage of the disease, low CD4 count, low weight and low haemoglobin levels at baseline were significant predictors of all-cause mortality during the follow-up

### Strengths and limitations

- Strengths of the study include the large sample size and the use of robust methods to relate baseline predictors to the outcome occurrence during follow-up.
- The study was based on data collected from patient files and clinical registers, and as expected there were missing data, particularly on the true outcome of patients were lost-to-follow-up.

## INTRODUCTION

Human immunodeficiency virus (HIV) infection is a major global health problem. Sub-Saharan Africa (SSA), with about 68% of the global population with HIV, is the most affected region in the world. [1] HIV related mortality appears to be higher in developing than in developed countries. [2] Hopefully, mortality rates are on the decline with the improved access to antiretroviral therapy, [3] while explaining factors of the residual deaths seems to vary significantly across populations. Studies in SSA have found that mortality rate is particularly high during the first year of starting antiretroviral therapy, [4] with male sex, cachexia, advanced stage of the disease, low CD4 count, anaemia, high viral load at baseline, and poor adherence to treatments being the main determinants of death. [5-8]

In Cameroon, about 105,000 people with HIV infection were on antiretroviral therapy by the end of the year 2011, [9] A study conducted in 2006 in a rural unit for HIV treatment in the northern part of the country, found a mortality rate of 20.2/100 person-years among HIV patients receiving antiretroviral therapy. [10] This figure however, has not been updated since the introduction of free access to antiretroviral therapy in the country. Thus, the aim of this study was to determine the mortality rate and its determinants among patients with HIV-1 infection, started on antiretroviral therapy in a reference treatment centre in Cameroon.

## PARTICIPANTS AND METHODS

### Study setting

The study was conducted in the approved HIV treatment centre of the Yaounde Jamot Hospital (YJH) in the Capital city of Cameroon. The study setting has been described in detail previously elsewhere. [11, 12] In brief, YJH is the referral centre for tuberculosis and chest diseases for the Capital city (Yaounde) and surrounding areas. It has an approved treatment centre (ACT) that provides care to people with HIV infection. As of June 2011, the active file of HIV infected persons followed in the centre was 2250 patients.

### *Care of patients with HIV infection*

During the study period, patients with HIV infection were started on antiretroviral therapy in the presence of a CD4 count below 200/mm<sup>3</sup> or superimposed condition other than tuberculosis, characteristic of WHO stage IV of the disease severity, [13] Patients fulfilling these criteria were referred to the ACT for treatment inception and follow-up. A medical file was created under the supervision of the attending physician and included socio demographic, clinical and biological data

1 of the patient. Files of eligible patients were presented at weekly meetings during which the  
2 appropriate treatment regimen for each patient was decided. First line treatment regimens included  
3 two nucleoside reverse transcriptase inhibitors (zidovudine, didanosine, lamivudine, tenofovir) and  
4 one non-nucleoside reverse transcriptase inhibitor (nevirapine or efavirenz). Second line regimens  
5 comprised two nucleoside reverse transcriptase inhibitors (zidovudine, didanosine, lamivudine,  
6 tenofovir) and a protease inhibitor (indinavir, lopinavir/ritonavir). These regimens were all  
7 dispensed to patients free of charge and they were all started on prophylactic treatment with  
8 cotrimoxazole. All patients had a session with trained psychosocial advisors, to improve adherence  
9 to prescribed therapies.

10 Patients registered at the YJH's ACT are seen on a monthly basis for prescription renewal.  
11 For those on a regimen comprising zidovudine (AZT) and/or nevirapine (NVP), haemoglobin  
12 (AZT) and/or liver transaminases (NVP) levels are monitored at two weeks from starting treatment.  
13 A biological profile is requested every six months, comprising a CD4 count, full blood count, liver  
14 transaminases and creatinin (only for patients receiving tenofovir), and results are recorded in the  
15 clinical file.

## 26 Outcome

27 During the study period, patients who failed to report for consultation for three consecutive  
28 months were traced by community liaison agents using the contact details on the file. All-cause  
29 mortality was considered for all deceased patients at any time after starting antiretroviral therapy.  
30 The time-to-death (in months) was the interval from the start of the antiretroviral therapy to date of  
31 death (or date of the last recorded visit when the date of death was unknown). Loss-to-follow-up  
32 (defaulter) was considered for patients who failed to return for consultation for three consecutive  
33 months and was unsuccessfully traced by liaison agents, [14] Transfer was considered for patients  
34 who at any time were definitively transferred to receive care in another centre. The follow-up for all  
35 patients was until June 2012, death, transfer and loss to follow-up, whichever came first.

## 36 Data collection

37 For the purpose of this study, patients with HIV started on antiretroviral therapy between  
38 January 2007 and December 2008 were identified via antiretroviral treatment registries. All patients  
39 with HIV-1 infection, aged 18 years and above, started on antiretroviral during this period were  
40 included in the study, and followed until June 2012 (5.5 years). The study was approved by the  
41 regulatory board of YJH.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
The following data were then retrieved in the medical files of eligible patients: sex, baseline age (in years), residence (urban vs. rural), weight, presence of opportunistic infection, CD4 count, haemoglobin levels, total lymphocytes and platelet counts, antiretroviral regimens; the outcome, and estimated time to the outcome occurrence. The duration of follow-up for patients still actively followed-up was censored in June 2012.

### 11 **Statistical analysis**

12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
Data analysis used SPSS v17.0 (SPSS Inc., Chicago, USA) and SAS/STAT® v 9.1 for Windows (SAS Institute Inc., Cary, NC, USA). Results are presented as count and percentages, mean and standard deviation or median and 25<sup>th</sup>-75<sup>th</sup> percentiles. The chi square test, Student's t-test and equivalents were used to compare baseline characteristics. The Kaplan-Meier estimator and accelerated failure time models, implemented with the use of LIFETEST and LIFEREG procedures of SAS were used to investigate the baseline characteristics associated with mortality during the first 60 months of follow-up (corresponding to the observed duration of follow-up for > 95% of participants). A p-value < 0.05 was used to characterise statistically significant results.

## 31 **RESULTS**

### 32 **Baseline characteristics of the study population**

33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
In 2007 and 2008, a total of 1444 patients with HIV infection [including 827 women (57.3%)] were started on antiretroviral treatment at the YJH's ACT. Medical files were available for all of them. However, data were missing on some characteristics for few participants. Analyses for those characteristics are restricted to participants with valid data, and their number indicated where relevant. The baseline demographic, clinical and biological characteristics of participants are summarised in Table 1. The median age (25<sup>th</sup>-75<sup>th</sup> percentiles) was 38 (31 - 45) years overall, 40 (34 - 47) years in men and 35 (30 - 43) years in women,  $p < 0.0001$ . In all 85.6% of participants were urban dwellers and about the same proportion were started on antiretroviral therapy at WHO stage III-IV of disease severity, similarly among men and women (both  $p \geq 0.82$ , Table 1). The main opportunistic infection was tuberculosis, which was found in 428 (29.6%) patients, and was more frequent in men than in women (34.7% vs. 27.9%,  $p = 0.0003$ ). The median CD4 count (25<sup>th</sup>-75<sup>th</sup> percentiles) was 99 (36 - 161) per mm<sup>3</sup> overall, 89 (33 - 155) in men and 105 (39 - 166) in women ( $p = 0.018$ ).

## Follow-up and outcome

The median duration of follow-up (25<sup>th</sup> - 75<sup>th</sup> percentiles) was 14.4 (1.0 - 46.2) months overall, 9.1 (0 - 44.1) months in men and 20.3 (1.3 - 47.3) months in women (p = 0.0001). At the final evaluation, 235 (cumulative incidence rate 16.3%) were deceased, 590 (40.8%) were lost to follow-up, 173 (12%) had been transferred to another centre, while 446 patients (30.9%) were still under active follow-up in the centre. The median duration of follow-up (25<sup>th</sup> - 75<sup>th</sup> percentiles) for non-fatal outcomes was 4.5 (0-23.8) months for defaulters, 8.2 (2.5 -20.3) months for transfer out, and 50.5 (45.9 - 56.7) months for active follow-up cases.

Of the 235 deaths recorded, 208 (88.5 %) deaths occurred early (within the first year of ART) while 27 (11.5 %) were late-occurring deaths. Overall, 54.9 % of all deaths occurred within one month of starting antiretroviral therapy, 19.6 % between 1 and 3 months, 8.5 % between 3 and 6 months and 5.5% between 6 and 12 months. The cumulative survival probability from Kaplan-Meier estimators was 84.7% (95 % confidence interval: 82.7 - 86.7) at 6 months, 83.3% (81.3 - 85.4) at 12 months, 81.7% (79.5 - 83.9) at 24 months, and 79.3% (76.0 - 82.5) at 60 months of follow-up. The survival probability from Kaplan-Meier estimators and Weibull plot of the cumulative distribution function for all-cause mortality are depicted in Figure 1.

## Determinants of all-cause mortality

The estimated cumulative distribution function for all-cause mortality by major subgroups is depicted in figure 2. In sex and age adjusted analyses, male sex, active tuberculosis, WHO stage III-IV of the disease, lower weight, lower CD4 count and lower baseline haemoglobin level were potential determinants of all-cause mortality (Table 2). In multivariable Weibull regression models with simultaneous adjustment for age, sex, and all the potential factors, all determinants remained significantly associated with all-cause mortality during follow-up (Table 2). Effect estimates (hazard ratio) and 95% confidence intervals were 2.15 (1.34-3.45) for male sex, 2.35 (1.40-3.92) for active tuberculosis, 3.63 (1.29-10.24) for WHO stage III-IV of the disease severity, 1.03 (1.01-1.05) per kilogram lower weight, 1.04 (1.01-1.07) per 10 lower CD4/mm<sup>3</sup> and 1.12 (1.00-1.26) for each g/dl lower baseline haemoglobin (Table 2).

## DISCUSSION

This study conducted in a referral centre for tuberculosis and HIV care in Cameroon revealed a high mortality rate among patients started on antiretroviral therapy, with the large majority of death occurring during the first year of starting the treatment. Male gender, active tuberculosis, advanced stage of the disease, low CD4 count, low weight and low haemoglobin



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

levels at baseline were significant predictors of all-cause mortality during follow-up. Accounting for these factors may help in refining the prescription of antiretroviral therapy and improve the outcome of care among patients with HIV infection.

The survival probability at one year of follow-up after starting antiretroviral therapy was found to be much lower (83.3% vs. 77%) in a previous study among 1187 patients with HIV infection in a rural setting in the Northern part of Cameroon. [10] This study however, was conducted prior to the implementation of the program of free access to antiretroviral therapy in the country, which suggests that this strategy has likely improved survival among HIV patients in the country. It can also be speculated that the difference between this previous study and our study just reflects differences in the level of care provided in a referral centre like ours, and a rural centre where care can be very basic. The similarities in the baseline profile of participants across the two studies are in support of this hypothesis. For instance, in both studies over 85% of participants were started on antiretroviral therapy while at the WHO stage III or IV of the disease severity, while pre-ARV CD4 count was lower than 50/mm<sup>3</sup> in over a quarter of participants at baseline. However, the one-year survival rate in our study is within the range of those reported in previous studies. In recent meta-analysis of those studies, the pooled estimated one-year probability of death from studies conducted in Africa was 17% (95% confidence interval: 11-24%), [6, 15]

Predictors of mortality identified in our study were essentially those described in existing reports, [6, 15] The adverse profile of modifiable risk factors clearly suggest that patients with HIV in our centre are started on ART at an advanced stage of the disease. This likely reflects the fact that in this setting, with the exception of screening in particular circumstances such as during pregnancy or pre-surgical intervention, people with HIV infection mostly get screened only when they seek medical care with clinical symptoms. This is a common attitude across Africa, which may explain the higher early mortality rate on ART in Africa, compared with other parts of the world, [6] In addition to the advanced clinical stage of the disease on the WHO scale at presentation, body weight, CD4 count and haemoglobin levels were low at baseline, and all significantly associated with high risk of mortality during follow-up as previously reported. [5-8] The prevalence of active tuberculosis in our study was possibly inflated by the nature of the study setting as a referral centre for tuberculosis treatment, where most patients with both HIV and tuberculosis are likely to be referred for care. The resulting subsample of participants with both conditions has possibly increased our statistical power for uncovering baseline active tuberculosis as a risk factor for fatal outcomes among people with HIV started on antiretroviral therapy. Such an association has been inconsistently reported in previous studies. [6, 10, 16]

1 The main non-modifiable risk factor of mortality in our study was male sex. This was not  
2 fully explained by sex differences in the level of other risk factors. Indeed, with the exception of  
3 baseline CD4 count which was lower in men, other factors were equally distributed among men or  
4 women or rather showed more favourable levels in men. Other studies have shown that adherence  
5 to prescribed ART was better in women than in men, [17] which can explain differing rates of fatal  
6 outcomes between men and women started on ART.  
7  
8  
9  
10

11 Our study has some limitations, including the missing data, which are expected for a study  
12 conducted based on data collected from patients files, and when dealing with large numbers of  
13 participants. Drop-out through losses to follow-up potentially include deceased patients, and may be  
14 in high proportion based on some studies. [18] Therefore, the reported mortality rate in our study is  
15 likely underestimated. But such a bias is unlikely to affect the associations of major risk factors  
16 with the mortality outcome as shown elsewhere. [10] Our study also has major strengths including  
17 the large sample size, which increased our statistical power to reliably characterise the predictors of  
18 mortality. The death rate following ART initiation as found in our study and previous studies is not  
19 constant over time. It is very high in the early months of starting the treatment, and subsequently  
20 drops and stabilises at a much lower rate. Many previous studies have been based on statistical  
21 methods that assume constant death rates over time such as the person-year methods, and have  
22 likely generated less reliable estimates. We have attempted to address this limitation by applying  
23 the accelerated failure time models in our study.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34

35 In conclusion, mortality rate among patients with HIV-1 infection started on antiretroviral  
36 therapy in this setting remain unacceptably high. Deaths occur mostly within the first year of  
37 starting treatment and essentially among patients with clinical and biological profiles compatible  
38 with an advanced stage of the disease at the time antiretroviral treatment is started. Strategies for  
39 early detection of patient with HIV and the clinically asymptomatic stages followed by early  
40 initiation of antiretroviral therapy needs to be developed and tested in this setting. Recent  
41 Cameroonian guidelines of HIV treatment allowing the prescription of antiretroviral therapy to  
42 patients with CD4 count lower than  $350/\text{mm}^3$  would probably reduce the mortality rate in this  
43 setting.  
44  
45  
46  
47  
48  
49

50 **Funding:** This research received no specific grant from any funding agency in the public,  
51 commercial or not-for-profit sectors.  
52  
53

54 **Competing interests:** None.  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Ethics approval:** Ethics approval was provided by the Institutional Review Board of Yaounde Jamot Hospital.

**Contributors:** VPM, collected data, co-analysed the data and drafted the manuscript. EWPY conceived the study, supervised data collection, co-analysed the data and drafted the manuscript. APK contributed to study design, data analysis, drafting and critical revision of the manuscript. CK supervised data collection and critically revised the manuscript. All authors approved the final version of the manuscript.

## REFERENCES

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Report on the global AIDS epidemic. 2012  
[http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120\\_UNAIDS\\_Global\\_Report\\_2012\\_en.pdf](http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_UNAIDS_Global_Report_2012_en.pdf) (Accessed 6 May 2013)
2. Braitstein P, Brinkhof MW, Dabis F *et al*. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. *Lancet* 2006;**367**:817-824.
3. Palella FJ, Baker RK, Moorman AC *et al*. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. *J Acquir Immune Defic Syndr* 2006;**43**:27-34.
4. Marazzi MC, Liotta G, Germano P *et al*. Excessive early mortality in the first year of treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited settings. *AIDS Res Hum Retroviruses* 2008;**24**:555-560.
5. Kouanda S, Meda IB, Nikiema L *et al*. Determinants and causes of mortality in HIV-infected patients receiving antiretroviral therapy in Burkina Faso: a five-year retrospective cohort study. *AIDS Care* 2012;**24**:478-90.
6. Gupta A, Nadkarni G, Yang WT *et al*. Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. *PLoS One* 2011;**6**:e28691.
7. Fregonese F, Collins IJ, Jourdain G *et al*. Predictors of 5-years mortality in HIV-infected adults starting highly active antiretroviral therapy (HAART) in Thailand. *J Acquir Immune Defic Syndr* 2012;**60**(1):91-8.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
8. Laurent C, Meilo H, Guiard-Schmid JB et al. Antiretroviral therapy in public and private routine health care clinics in Cameroon: lessons from the Douala antiretroviral (DARVIR) initiative. *Clin Infect Dis* 2005;**41**:108-111.
9. Ministère de la Santé Publique. Rapport national de suivi de la déclaration politique sur le VIH/SIDA Cameroun 2012.
10. Sieleunou I, Souleymanou M, Schonenberger AM et al. Determinants of survival in AIDS patients on antiretroviral therapy in a rural centre in the Far-North Province, Cameroon. *Trop Med Int Health* 2009;**14**:36-43.
11. Pefura Yone EW, Betyoumin AF, Kengne AP et al. First-line antiretroviral therapy and dyslipidemia in people living with HIV-1 in Cameroon: a cross-sectional study. *AIDS Res Ther* 2011;**8**:33.
12. Pefura Yone EW, Soh E, Kengne AP et al. Non-adherence to antiretroviral therapy in Yaounde: Prevalence, determinants and the concordance of two screening criteria. *Journal of Infection and Public Health* 2013. doi:10.1016/j.jiph.2013.02.003
13. Ministère de la Santé Publique du Cameroun. Directives nationales de prise en charge par les antirétroviraux des personnes (adultes et adolescents) infectés par le VIH. Yaoundé 2007.
14. Wools-Kaloustian K, Kimaiyo S, Diero L et al. Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. *Aids* 2006;**20**:41-48.
15. Biadgilign S, Reda AA, Digaffe T. Predictors of mortality among HIV infected patients taking antiretroviral treatment in Ethiopia: a retrospective cohort study. *AIDS Res Ther* 2012;**9**:15.
16. Amuron B, Levin J, Birunghi J et al. Mortality in an antiretroviral therapy programme in Jinja, south-east Uganda: a prospective cohort study. *AIDS Res Ther* 2011;**8**:39.
17. MacPherson P, Moshabela M, Martinson N et al. Mortality and loss to follow-up among HAART initiators in rural South Africa. *Trans R Soc Trop Med Hyg* 2009, **103**:588-593.
18. Yu JK, Chen SC, Wang KY et al. True outcomes for patients on antiretroviral therapy who are "lost to follow-up" in Malawi. *Bull World Health Organ* 2007;**85**:550-554.

Table 1 Demographic, clinical and biological profile of HIV patients started on antiretroviral therapy at the Yaounde Jamot Hospital in 2007 and 2008

Characteristics	Overall	Men	Women	p-value
n	1444	617	827	
Median age, years (25 <sup>th</sup> -75 <sup>th</sup> percentile)	38 (31-45)	40 (34-47)	35 (30-43)	<0.0001
Residence, n (%)				0.98
Urban	1236 (85.6)	528 (85.6)	708 (85.6)	
Rural	208 (14.4)	89 (14.4)	119 (14.4)	
Tuberculosis, n (%)	428 (29.6)	214 (34.7)	214 (27.9)	0.0003
Weight, Kg				<0.0001
< 50, n (%)	308/1322 (23.3)	69/570 (12.1)	239/752 (31.8)	
50-60, n (%)	535/1322 (40.5)	204/570 (35.8)	331/752 (44.0)	
>60, n (%)	479/1322 (36.2)	297/570 (52.1)	182/752 (24.2)	
Median (25 <sup>th</sup> -75 <sup>th</sup> percentile)	57 (50 - 65)	61 (54-68)	54 (47.5-60)	<0.0001
WHO stage, n (%)				0.82
I and II	186/1295 (14.4)	78/553 (14.1)	108/742 (14.6)	
III and IV	1109/1295 (85.6)	475/553 (85.9)	634/742 (85.4)	
Platelets, X1000/mm <sup>3</sup>	244 (180– 320)	229 (173-309)	259 (190-330)	0.0005
Total lymphocytes, X10/mm <sup>3</sup>	130 (90–190)	130 (90-201)	130 (90-190)	0.88
CD4, /mm <sup>3</sup>				0.21
< 50, n (%)	468 (32.4)	216 (30.5)	256 (30.5)	
50-99, n (%)	257 (17.8)	111 (18.0)	142 (17.6)	
100-200, n (%)	562 (38.9)	231 (37.4)	331 (40.0)	
>200, n (%)	157 (10.9)	59 (9.6)	98 (11.8)	
Median (25 <sup>th</sup> -75 <sup>th</sup> percentile)	99 (36.2-161)	89 (33-155)	105 (39-166)	0.018
Haemoglobin, g/dl,				<0.0001
< 8, n (%)	235/1388 (16.9)	67/594 (11.3)	168/794 (21.2)	
8-10, n (%)	506/1388 (36.5)	178/594 (30.0)	328/794 (41.3)	
>10, n (%)	647/1388 (46.6)	349 (58.7)	298 (37.5)	
Median, (25 <sup>th</sup> -75 <sup>th</sup> percentile)	9.9 (8.5-11.2)	10.5 (9-12)	9.5 (8.1-10.7)	<0.0001

NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; WHO, World Health Organisation

Table 2 Determinants of all-cause mortality among HIV-positive patients started on antiretroviral therapy

Variable	Age and sex adjusted		Multivariable adjusted	
	Hazard Ratio (95% CI)	p	Hazard Ratio (95% CI)	p
Age, per year	1.01 (0.98-1.03)	0.56	1.01 (0.99-1.03)	0.37
Male sex	1.44 (0.94-2.11)	0.10	2.15 (1.34-3.45)	0.002
Rural residency	1.14 (0.62-2.09)	0.68	-	
Active tuberculosis	1.59 (0.97-2.61)	0.07	2.35 (1.40-3.92)	0.002
WHO stage III-IV	4.57 (1.68-12.47)	0.004	3.63 (1.29-10.24)	0.02
Weight, per kg lower	1.04 (1.02-1.06)	0.0002	1.03 (1.01-1.05)	0.01
Platelet count, per 1000 lower	1.01 (0.99-1.03)	0.53	-	
CD4 count, per 10/mm <sup>3</sup> lower	1.06 (1.02-1.09)	0.003	1.04 (1.01-1.07)	0.02
Haemoglobin, per g/dl lower	1.14 (1.03-1.26)	0.02	1.12 (1.00-1.26)	0.05
AZT based regimens	0.91 (0.51-1.62)	0.76	-	

AZT, zidovudine; CI, confidence interval; WHO, World Health Organisation




Figure 1: Survival probability from Kaplan-Meier estimator (upper panel) and Weibull plot showing the cumulative distribution function for mortality during follow-up of patients with HIV infection who started antiretroviral treatment at the Yaounde Jamot Hospital in 2007 and 2008  
203x196mm (96 x 96 DPI)






Figure 2: Estimated cumulative distribution function for all-cause mortality by major subgroups among patients with HIV infection who started antiretroviral treatment at the Yaounde Jamot Hospital in 2007 and 2008  
203x160mm (96 x 96 DPI)

view only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Pages
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	4,5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4,5
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	4,5
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	/
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	/
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed	/
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	/
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	/
Bias	9	Describe any efforts to address potential sources of bias	5
Study size	10	Explain how the study size was arrived at	4,5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6
		(b) Describe any methods used to examine subgroups and interactions	/
		(c) Explain how missing data were addressed	/
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	/
		<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	
		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	

Continued on next page

**Results**

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	6
		(b) Give reasons for non-participation at each stage	/
		(c) Consider use of a flow diagram	/
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	6,7
		(b) Indicate number of participants with missing data for each variable of interest	12
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	7
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	7
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	/
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	13
		(b) Report category boundaries when continuous variables were categorized	/
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	/
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	/

**Discussion**

Key results	18	Summarise key results with reference to study objectives	7,8
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	9
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	7,8,9
Generalisability	21	Discuss the generalisability (external validity) of the study results	9

**Other information**

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	9
---------	----	---	---

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).



**Mortality and its determinants among patients infected with HIV-1 on antiretroviral therapy in a referral centre in Yaounde, Cameroon: a retrospective cohort study**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-003210.R1
Article Type:	Research
Date Submitted by the Author:	27-May-2013
Complete List of Authors:	Poka-Mayap, Virginie; Yaounde Jamot Hospital, Pneumology Service Pefura-Yone, Eric Walter; Yaounde Jamot Hospital, Pneumology Service; Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Department of Internal Medicine and Subspecialties Kengne, Andre; South African Medical Research Council, Kuaban, Christopher; Faculty of Health Sciences, University of Bamenda, ; Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Department of Internal Medicine and Subspecialties
<b>Primary Subject Heading</b>:	HIV/AIDS
Secondary Subject Heading:	Epidemiology
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, Epidemiology < INFECTIOUS DISEASES, EPIDEMIOLOGY
<p>Note: The following files were submitted by the author for peer review, but cannot be converted to PDF. You must view these files (e.g. movies) online.</p> <p>Research Checklist Determinants of deaths HIV.doc</p>	

SCHOLARONE™  
Manuscripts

1  
2 **Mortality and its determinants among patients infected with HIV-1 on antiretroviral therapy**  
3 **in a referral centre in Yaounde, Cameroon: a retrospective cohort study**  
4

5  
6 **Short title: Determinants of death among patients with HIV infection**  
7

8 Virginie POKA-MAYAP (1), Eric Walter PEFURA-YONE (1, 2), André Pascal KENGNE (3),  
9 Christopher KUABAN (1, 4)  
10

- 11  
12 1) Pneumology Service, Yaounde Jamot Hospital, Cameroon  
13  
14 2) Department of Internal Medicine and Subspecialties, Faculty of Medicine and Biomedical  
15 Sciences, University of Yaounde I, Cameroon  
16  
17 3) South African Medical Research Council & University of Cape Town, Cape Town, South  
18 Africa  
19  
20 4) Faculty of Health Sciences, University of Bamenda, Cameroon  
21  
22  
23  
24

25 **Correspondence to:**  
26

27 Dr Virginie Poka-Mayap,  
28  
29 Yaounde Jamot Hospital,  
30  
31 PO Box 4021-Yaounde, Cameroon  
32  
33  
34 Tel: (237)99253759,  
35  
36  
37 Email: [pokavirginie@yahoo.fr](mailto:pokavirginie@yahoo.fr)  
38  
39

40 **Tables: 2**  
41

42 **Figures: 0**  
43

44 **Online only material: 0**  
45

46  
47 **Word count:** abstract-288; Main text (excluding tables, figures, abstract & references)-3017  
48

49 **References: 19**  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**ABSTRACT**

**Objectives:** Mortality has decreased in people with human immunodeficiency virus (HIV) infection, subsequent to the improved access to antiretroviral therapy (ART). We assessed the incidence and determinants of mortality among patients with HIV-1 infection, started on ART in a referral treatment centre for HIV infection in Yaounde, Cameroon.

**Design:** Cohort study with baseline assessment between 2007 and 2008, and follow-up during five years until June 2012.

**Setting:** The accredited HIV treatment centre of the Yaounde Jamot Hospital, in capital city of Cameroon.

**Participants:** People living with HIV infection who started ART between 2007 and 2008 at the study centre.

**Outcome measures:** All-cause mortality over time, with the accelerated failure time models were used to relate baseline characteristics with mortality occurrence during follow-up.

**Results:** Of the 1444 patients included, 827 (53.7 %) were men, and the median age (25<sup>th</sup>-75<sup>th</sup> percentiles) was 38 (31- 45) years. The median duration of follow-up was 14.1 (1.1 - 46.4) months, during which 235 deaths were recorded (cumulative incidence rate: 16.3 %), including 208 (88.5 %) during the first year of follow-up. Baseline predictors of mortality were male gender [adjusted hazard ratio 2.15 (95 % Confidence Interval : 1.34 - 3.45)], active tuberculosis [2.35 (1.40 - 3.92)], WHO stages III-IV of the disease [3.63 (1.29 - 10.24)], low weight [1.03 (1.01-1.05) per kilogramme], low CD4 count [1.04 (1.01 - 1.07) per 10/mm<sup>3</sup>] and low haemoglobin levels [1.12 (1.00 - 1.26) per g/dl].

**Conclusions:** Death rate among patients with HIV is very high within the first year of starting ART in this centre. Early start of the treatment, at a less advanced stage of the disease, and much favourable levels of CD4 and other predictors could reduce early mortality, but would have to be tested.

*Word count – 288*

*Key words:* HIV infection, death, determinants, cohort, Cameroon, antiretroviral therapy

## ARTICLE SUMMARY

### Article focus

- To investigate mortality occurrence and determinants among patients with HIV-1 infection, started on antiretroviral therapy in a major reference treatment centre

### Key messages

- Death rate among patients with HIV is very high within the first year of starting antiretroviral therapy in this centre
- Male gender, active tuberculosis, advanced stage of the disease, low CD4 count, low weight and low haemoglobin levels at baseline were significant predictors of all-cause mortality during follow-up

### Strengths and limitations

- Strengths of the study include the large sample size and the use of robust methods to relate baseline predictors to the outcome occurrence during follow-up.
- The study was based on data collected from patient files and clinical registers, and as expected there were missing data, particularly on the true outcome of patients who were lost-to-follow-up.

## INTRODUCTION

Human immunodeficiency virus (HIV) infection is a major global health problem. Sub-Saharan Africa (SSA), with about 68 % of the global population with HIV, is the most affected region in the world. [1] HIV related mortality appears to be higher in developing than in developed countries. [2] Hopefully, mortality rates are on the decline with the improved access to antiretroviral therapy (ART), [3] while explaining factors of the residual deaths seems to vary significantly across populations. Studies in SSA have found that mortality rate is particularly high during the first year of starting antiretroviral therapy, [4] with male sex, cachexia, advanced stage of the disease, low CD4 count, anaemia, high viral load at baseline, and poor adherence to treatments being the main determinants of death. [5-8]

In Cameroon, about 105,000 people living with HIV (PLHIV) infection were on ART by the end of the year 2011, [9] A study conducted in 2006 in a rural unit for HIV treatment in the northern part of the country, found a mortality rate of 20.2/100 person-years among HIV patients receiving ART. [10] This figure however, has not been updated since 2007, year of the introduction of free access to ART in the country. Thus, the aim of this study was to determine the mortality rate and its determinants among patients with HIV-1 infection, started on ART in a reference treatment centre in Cameroon.

## PARTICIPANTS AND METHODS

### Study setting

The study was conducted in the accredited HIV treatment centre (ATC) of the Yaounde Jamot Hospital (YJH) in the Capital city of Cameroon. The study setting has been described in detail previously elsewhere. [11, 12] In brief, YJH is the referral centre for tuberculosis and chest diseases for the Capital city (Yaounde) and surrounding areas. It has an ATC that provides care to PLHIV. As of June 2011, a total of 2250 PLHIV were followed in the centre.

### *Care of patients with HIV infection*

During the study period, PLHIV were started on ART in the presence of a CD4 count below 200/mm<sup>3</sup> or superimposed condition of the WHO stage IV of the disease severity other than tuberculosis. [13] Patients fulfilling these criteria were referred to the ATC for treatment inception and follow-up. A medical file was created under the supervision of the attending physician and included socio demographic, clinical and biological data of the patient. Files of eligible patients were presented at weekly meetings during which the appropriate treatment regimen for each patient

1 was decided. First line treatment regimens included two nucleoside reverse transcriptase inhibitors  
2 (zidovudine, lamivudine, tenofovir) and one non-nucleoside reverse transcriptase inhibitor  
3 (nevirapine or efavirenz). Second line regimens comprised two nucleoside reverse transcriptase  
4 inhibitors (zidovudine, didanosine, lamivudine, tenofovir) and a protease inhibitor (indinavir,  
5 lopinavir/ritonavir). These regimens were all dispensed to patients free of charge and they were all  
6 started on prophylactic treatment with cotrimoxazole. All patients had a session with trained  
7 psychosocial advisors, to improve adherence to prescribed therapies.  
8  
9

10 Patients registered at the YJH's ATC are seen on a monthly basis for prescription renewal.  
11 For those on a regimen comprising zidovudine (AZT) and/or nevirapine (NVP), haemoglobin  
12 (AZT) and/or liver transaminases (NVP) levels are monitored at two weeks from starting treatment.  
13 A biological profile is requested every six months, comprising a CD4 count, full blood count, liver  
14 transaminases and creatinin (only for patients receiving tenofovir), and results are recorded in the  
15 clinical file.  
16  
17  
18  
19  
20  
21  
22  
23

## 24 Outcome

25 During the study period, patients who failed to report for consultation for three consecutive  
26 months were traced by community liaison agents using the contact details on the file. All-cause  
27 mortality was considered for all deceased patients at any time after starting ART. The time-to-death  
28 (in months) was the interval from the start of the ART to date of death (or date of the last recorded  
29 visit when the date of death was unknown). Loss-to-follow-up (defaulter) was defined as patients  
30 who failed to return for consultation for three consecutive months and were unsuccessfully traced  
31 by liaison agents, [14] Transfer was considered for patients who at any time were definitively  
32 transferred to receive care in another centre. The follow-up for all patients was until June 2012,  
33 death, transfer and loss to follow-up, whichever came first.  
34  
35  
36  
37  
38  
39  
40  
41  
42

## 43 Data collection

44 For the purpose of this study, patients with HIV started on ART between January 2007 and  
45 December 2008 were identified via antiretroviral treatment registries. All patients with HIV-1  
46 infection, aged 18 years and above, started on ART during this period were included in the study,  
47 and followed until June 2012 (5.5 years). The study was approved by the regulatory board of YJH.  
48  
49  
50  
51  
52

53 The following data were then retrieved in the medical files of eligible patients: sex, baseline  
54 age (in years), residence (urban vs. rural), weight in Kg, presence of opportunistic infection, CD4  
55 count (in cells/mm<sup>3</sup>), haemoglobin levels in g/dl, total lymphocytes and platelet counts,  
56 antiretroviral regimens; outcome (death, loss to follow up, transfer out, still alive and followed up),  
57  
58  
59  
60



1 and estimated time to the outcome occurrence in months. The duration of follow-up for patients still  
2 actively followed-up was censored in June 2012.  
3  
4

## 5 6 **Statistical analysis**

7  
8 Data analysis used SPSS v17.0 (SPSS Inc., Chicago, USA) and SAS/STAT® v 9.1 for  
9 Windows (SAS Institute Inc., Cary, NC, USA). Results are presented as count and percentages,  
10 mean and standard deviation or median and 25<sup>th</sup>-75<sup>th</sup> percentiles. The chi square test, Student's t-  
11 test and their non-parametric equivalents were used to compare baseline characteristics. The  
12 Kaplan-Meier estimator and accelerated failure time models, implemented with the use of  
13 LIFETEST and LIFEREG procedures of SAS were used to investigate the baseline characteristics  
14 associated with mortality during the first 60 months of follow-up (corresponding to the observed  
15 duration of follow-up for > 95% of participants). Candidate predictors included age (in years),  
16 gender (male vs. female), residency (rural vs. urban), active tuberculosis, WHO stages of the  
17 disease (III-IV vs. I-II), weight (in kg), platelet count (per 1000), CD4 count (per 10/mm<sup>3</sup>),  
18 haemoglobin level (in g/dl) and ART regimen (AZT vs. no AZT). Candidate predictors were tested  
19 one at a time in a basic model that included gender and age as covariates. Then significant  
20 predictors (based on a p-value <0.10) were entered together in a multivariable model, and  
21 significant ones kept in the final model alongside age and gender. The reference category (or  
22 direction of continuous predictors) was always rearranged as appropriate to identify levels  
23 associated with increased mortality risk. A p-value < 0.05 was used to characterise statistically  
24 significant results.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

## 37 **RESULTS**

### 38 **Data available**

39  
40 In 2007 and 2008, a total of 1444 PLHIV [including 827 women (57.3 %)] were started on ART at  
41 the YJH's ATC. Medical files were available for all of them. However, data were missing on some  
42 characteristics for few participants. Analyses for those characteristics are restricted to participants  
43 with valid data, and their number indicated where relevant. Furthermore, a total of 470 participants  
44 had missing data for at least one of the candidate predictors, and were therefore excluded from  
45 regression analysis. Compared with excluded participants, the 974 included in regression analysis  
46 had similar age (38.3 vs. 38.8 years, p = 0.44), mean CD4 count (102 vs. 111/mm<sup>3</sup>, p = 0.06).  
47 Furthermore, they had similar proportion of men (42.5 % vs. 43.2 %, p = 0.82), similar distribution  
48 across WHO stages of disease severity (p = 0.75), a borderline higher prevalence of active  
49 tuberculosis (31.1% vs. 26.6%, p = 0.044), a borderline lower baseline weight (57.6 vs. 59.1 kg,  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

p=0.045) and lower platelet ( $262000$  vs.  $243000/\text{mm}^3$ ,  $p = 0.035$ ), and a significantly lower haemoglobin level ( $9.9$  vs.  $10.4$  g/dl,  $p < 0.001$ ).

### Baseline characteristics of the study population

The baseline demographic, clinical and biological characteristics of participants are summarised in Table 1. The median age (25<sup>th</sup>-75<sup>th</sup> percentiles) was 38 (31 - 45) years overall, 40 (34 - 47) years in men and 35 (30 - 43) years in women,  $p < 0.0001$ . In all 85.6 % of participants were urban dwellers and about the same proportion were started on ART at WHO stage III-IV of disease severity, similarly among men and women (both  $p \geq 0.82$ , Table 1). The main opportunistic infection was tuberculosis, which was found in 428 (29.6 %) patients, and was more frequent in men than in women (34.7 % vs. 27.9 %,  $p = 0.0003$ ). The median CD4 count (25<sup>th</sup> - 75<sup>th</sup> percentiles) was 99 (36 - 161) per  $\text{mm}^3$  overall, 89 (33 - 155) in men and 105 (39 - 166) in women ( $p = 0.018$ ).

### Follow-up and outcome

The median duration of follow-up (25<sup>th</sup> - 75<sup>th</sup> percentiles) was 14.4 (1.0 - 46.2) months overall, 9.1 (0 - 44.1) months in men and 20.3 (1.3 - 47.3) months in women ( $p < 0.0001$ ). At the final evaluation, 235 (cumulative incidence rate 16.3 %) were deceased, 590 (40.8 %) were lost to follow-up, 173 (12 %) had been transferred to another centre, while 446 patients (30.9 %) were still under active follow-up in the centre. The median duration of follow-up (25<sup>th</sup> - 75<sup>th</sup> percentiles) for non-fatal outcomes was 4.5 (0 - 23.8) months for defaulters, 8.2 (2.5 - 20.3) months for transfer out, and 50.5 (45.9 - 56.7) months for active follow-up cases.

Of the 235 deaths recorded, 208 (88.5 %) deaths occurred early (within the first year of ART) while 27 (11.5 %) were late-occurring deaths. Overall, 54.9 % of all deaths occurred within one month of starting antiretroviral therapy, 19.6 % between 1 and 3 months, 8.5 % between 3 and 6 months and 5.5% between 6 and 12 months. The cumulative survival probability from Kaplan-Meier estimators was 84.7 % (95 % confidence interval: 82.7 - 86.7) at 6 months, 83.3 % (81.3 - 85.4) at 12 months, 81.7 % (79.5 - 83.9) at 24 months, and 79.3% (76.0 - 82.5) at 60 months of follow-up. The survival probability from Kaplan-Meier estimators and Weibull plot of the cumulative distribution function for all-cause mortality are depicted in Figure 1. The cumulative mortality rate was 16.8 % (79/470) among participants with missing data on at least one of the candidate predictor variables, and 16.6 % (162/974) among those with valid data,  $p = 0.93$ .

## Determinants of all-cause mortality

The estimated cumulative distribution function for all-cause mortality by major subgroups is depicted in figure 2. In sex and age adjusted analyses, male sex, active tuberculosis, WHO stage III-IV of the disease, lower weight, lower CD4 count and lower baseline haemoglobin level were potential determinants of all-cause mortality (Table 2). In multivariable Weibull regression models with simultaneous adjustment for age, sex, and all the potential factors, all determinants remained significantly associated with all-cause mortality during follow-up (Table 2). Effect estimates (hazard ratio) and 95% confidence intervals were 2.15 (1.34 - 3.45) for male sex, 2.35 (1.40 - 3.92) for active tuberculosis, 3.63 (1.29 - 10.24) for WHO stage III-IV of the disease severity, 1.03 (1.01 - 1.05) per kilogram lower weight, 1.04 (1.01 - 1.07) per 10 lower CD4/mm<sup>3</sup> and 1.12 (1.00 - 1.26) for each g/dl lower baseline haemoglobin (Table 2).

## DISCUSSION

This study conducted in a referral centre for tuberculosis and HIV care in Cameroon revealed a high mortality rate among patients started on ART, with the large majority of death occurring during the first year of starting the treatment. Male gender, active tuberculosis, advanced stage of the disease, low CD4 count, low weight and low haemoglobin levels at baseline were significant predictors of all-cause mortality during follow-up. Accounting for these factors may help in refining the prescription of ART and improve the outcome of care among patients with HIV infection.

The survival probability at one year of follow-up after starting ART was found to be much lower (83.3 % vs. 77 %) than in a previous study among 1187 PLHIV infection in a rural setting in the Northern part of Cameroon. [10] This study however, was conducted prior 2007, year of the implementation of the program of free access to ART in the country, which suggests that this strategy has likely improved survival among PLHIV in the country. It can also be speculated that the difference between this previous study and our study just reflects differences in the level of care provided in a referral centre like ours, and a rural centre where care can be very basic. The similarities in the baseline profile of participants across the two studies are in support of this hypothesis. For instance, in both studies over 85 % of participants were started on ART while at the WHO stage III or IV of the disease severity, while pre-ARV CD4 count was lower than 50/mm<sup>3</sup> in over a quarter of participants at baseline. However, the one-year survival rate in our study is within the range of those reported in previous studies. In recent meta-analysis of those studies, the pooled estimated one-year probability of death from studies conducted in Africa was 17 % (95 % confidence interval: 11-24 %), [6, 15]

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Predictors of mortality identified in our study were essentially those described in existing reports. [6, 15] The adverse profile of modifiable risk factors clearly suggests that patients with HIV in our centre are started on ART at an advanced stage of the disease. This likely reflects the fact that in this setting, with the exception of screening in particular circumstances such as during pregnancy or pre-surgical intervention, PLHIV mostly get screened only when they seek medical care with clinical symptoms. This is a common attitude across Africa, which may explain the higher early mortality rate on ART in Africa, compared with other parts of the world.[6] In addition to the advanced clinical stage of the disease on the WHO scale at presentation, body weight, CD4 count and haemoglobin levels were low at baseline, and all significantly associated with high risk of mortality during follow-up as previously reported. [5-8] It is of note that at the time this study was conducted, most patients were started on ART at CD4 count below 200/mm<sup>3</sup>. Recent WHO recommendations favour ART initiation at CD4 count below 350/mm<sup>3</sup>. Their uptake may potentially reduce early mortality rate, as a result of many patients starting treatment at favourable CD4 levels. The prevalence of active tuberculosis in our study was possibly inflated by the nature of the study setting as a referral centre for tuberculosis treatment, where most patients with both HIV and tuberculosis are likely to be referred for care. The resulting subsample of participants with both conditions has possibly increased our statistical power for uncovering baseline active tuberculosis as a risk factor for mortality among PLHIV started on antiretroviral therapy. Such an association has been inconsistently reported in previous studies. [6, 10, 16]

Free access to ART was introduced in Cameroon in May 2007 [17]. We have recently reported rate of non-adherence to ART to be as high as 34 % among patients with HIV receiving chronic care at the YJH in the era of free access to ART [12]. In the absence of any assessment of the adherence to ART in the current study, it is difficult to speculate of a contribution, if any, of non-adherence to ART to the observed high mortality in our study. However, such an effect is likely marginal in this setting where mortality mostly occurs early when patients have not been exposed to ART enough to derive therapeutic benefits. Furthermore, existing instruments for measuring adherence to ART are likely unsuitable for investigating premature mortality risk. The main non-modifiable risk factor of mortality in our study was male sex. This was not fully explained by sex differences in the level of other risk factors. Indeed, with the exception of baseline CD4 count which was lower in men, other factors were equally distributed among men or women or rather showed more favourable levels in men. Other studies have shown that adherence to prescribed ART was better in women than in men, [18] which can explain differing rates of mortality between men and women started on ART.

Our study has some limitations, including the missing data, which are expected for a study conducted based on data collected from patients files, and when dealing with large numbers of

1 participants. Drop-out through losses to follow-up potentially include deceased patients, and may be  
2 in high proportion based on some studies. [19] Therefore, the reported mortality rate in our study is  
3 likely underestimated. But such a bias is unlikely to affect the associations of major risk factors  
4 with the mortality outcome as shown elsewhere. [10] In the absence of any evaluation of the  
5 adherence to ART, particularly among early mortality survivors, we were unable to investigate a  
6 potential effect of non-adherence to ART on mortality risk in the current study. Our study also has  
7 major strengths including the large sample size, which increased our statistical power to reliably  
8 characterise the predictors of mortality. The death rate following ART initiation as found in our  
9 study and other published studies is not constant over time. It is very high in the early months of  
10 starting the treatment, and subsequently drops and stabilises at a much lower rate. Many previous  
11 studies have been based on statistical methods that assume constant death rates over time such as  
12 the person-year methods, and have likely generated less reliable estimates of the association of  
13 predictors with mortality risk. We have attempted to address this limitation by applying the  
14 accelerated failure time models in our study. Unlike Cox models for instance, regression parameters  
15 estimates from accelerated failure time models are robust to the omitted covariates, and are  
16 unaffected by the choice of probability distribution.

17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
In conclusion, mortality rate among patients with HIV-1 infection started on antiretroviral  
therapy in this setting remain unacceptably high. Deaths occur mostly within the first year of  
starting treatment and essentially among patients with clinical and biological profiles compatible  
with an advanced stage of the disease at the time when antiretroviral treatment is started. Strategies  
for early detection of patient with HIV and the clinically asymptomatic stages followed by early  
initiation of antiretroviral therapy needs to be developed and tested in this setting. Recent  
Cameroonian guidelines of HIV treatment allowing the prescription of antiretroviral therapy to  
patients with CD4 count lower than  $350/\text{mm}^3$  would probably reduce the mortality rate in this  
setting.

**Funding:** This research received no specific grant from any funding agency in the public,  
commercial or not-for-profit sectors.

**Competing interests:** None.

**Ethics approval:** Ethics approval was provided by the Institutional Review Board of Yaounde  
Jamot Hospital.

**Contributors:** VPM, collected data, co-analysed the data and drafted the manuscript. EWPY  
conceived the study, supervised data collection, co-analysed the data and drafted the manuscript.

1  
2 APK contributed to study design, data analysis, drafting and critical revision of the manuscript. CK  
3 supervised data collection and critically revised the manuscript. All authors approved the final  
4 version of the manuscript.  
5  
6  
7  
8  
9

## 10 REFERENCES

- 11  
12 1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Report on the global AIDS  
13 epidemic. 2012  
14 [http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr201](http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_UNAIDS_Global_Report_2012_en.pdf)  
15 [2/20121120\\_UNAIDS\\_Global\\_Report\\_2012\\_en.pdf](http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_UNAIDS_Global_Report_2012_en.pdf) (Accessed 6 May 2013)  
16  
17
- 18 2. Braitstein P, Brinkhof MW, Dabis F *et al*. Mortality of HIV-1-infected patients in the first  
19 year of antiretroviral therapy: comparison between low-income and high-income countries.  
20 *Lancet* 2006;**367**:817-824.  
21  
22
- 23 3. Palella FJ, Baker RK, Moorman AC *et al*. Mortality in the highly active antiretroviral  
24 therapy era: changing causes of death and disease in the HIV outpatient study. *J Acquir*  
25 *Immune Defic Syndr* 2006;**43**:27-34.  
26  
27
- 28 4. Marazzi MC, Liotta G, Germano P *et al*. Excessive early mortality in the first year of  
29 treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited  
30 settings. *AIDS Res Hum Retroviruses* 2008;**24**:555-560.  
31  
32
- 33 5. Kouanda S, Meda IB, Nikiema L *et al*. Determinants and causes of mortality in HIV-  
34 infected patients receiving antiretroviral therapy in Burkina Faso: a five-year retrospective  
35 cohort study. *AIDS Care* 2012;**24**:478-90.  
36  
37
- 38 6. Gupta A, Nadkarni G, Yang WT *et al*. Early mortality in adults initiating antiretroviral  
39 therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-  
40 analysis. *PLoS One* 2011;**6**:e28691.  
41  
42
- 43 7. Fregonese F, Collins IJ, Jourdain G *et al*. Predictors of 5-years mortality in HIV-infected  
44 adults starting highly active antiretroviral therapy (HAART) in Thailand. *J Acquir Immune*  
45 *Defic Syndr* 2012;**60**:91-8.  
46  
47
- 48 8. Laurent C, Meilo H, Guiard-Schmid JB *et al*. Antiretroviral therapy in public and private  
49 routine health care clinics in Cameroon: lessons from the Douala antiretroviral (DARVIR)  
50 initiative. *Clin Infect Dis* 2005;**41**:108-111.  
51  
52
- 53 9. Ministère de la Santé Publique. Rapport national de suivi de la déclaration politique sur le  
54 VIH/SIDA Cameroun 2012.  
55  
56  
57  
58  
59  
60



10. Sieleunou I, Souleymanou M, Schonenberger AM et al. Determinants of survival in AIDS patients on antiretroviral therapy in a rural centre in the Far-North Province, Cameroon. *Trop Med Int Health* 2009;**14**:36-43.
11. Pefura Yone EW, Betyoumin AF, Kengne AP et al. First-line antiretroviral therapy and dyslipidemia in people living with HIV-1 in Cameroon: a cross-sectional study. *AIDS Res Ther* 2011;**8**:33.
12. Pefura Yone EW, Soh E, Kengne AP et al. Non-adherence to antiretroviral therapy in Yaounde: Prevalence, determinants and the concordance of two screening criteria. *Journal of Infection and Public Health* 2013. doi:10.1016/j.jiph.2013.02.003.
13. Ministère de la Santé Publique du Cameroun. Directives nationales de prise en charge par les antirétroviraux des personnes (adultes et adolescents) infectés par le VIH. Yaoundé 2007.
14. Wools-Kaloustian K, Kimaiyo S, Diero L et al. Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. *Aids* 2006;**20**:41-48.
15. Biadgilign S, Reda AA, Digaffe T. Predictors of mortality among HIV infected patients taking antiretroviral treatment in Ethiopia: a retrospective cohort study. *AIDS Res Ther* 2012;**9**:15.
16. Amuron B, Levin J, Birunghi J et al. Mortality in an antiretroviral therapy programme in Jinja, south-east Uganda: a prospective cohort study. *AIDS Res Ther* 2011;**8**:39.
17. Ministry of Public Health, Republic of Cameroon. National AIDS Control Committee: Towards universal access to care and treatment for adults and children living with HIV/AIDS in Cameroon. Progress Report N° 4. 2006.
18. MacPherson P, Moshabela M, Martinson N et al. Mortality and loss to follow-up among HAART initiators in rural South Africa. *Trans R Soc Trop Med Hyg* 2009, **103**:588-593.
19. Yu JK, Chen SC, Wang KY et al. True outcomes for patients on antiretroviral therapy who are "lost to follow-up" in Malawi. *Bull World Health Organ* 2007;**85**:550-554.

Table 1 Demographic, clinical and biological profile of HIV patients started on antiretroviral therapy at the Yaounde Jamot Hospital in 2007 and 2008

Characteristics*	Overall	Men	Women	p-value
n	1444	617	827	
Median age, years (25 <sup>th</sup> -75 <sup>th</sup> percentile)	38 (31-45)	40 (34-47)	35 (30-43)	<0.0001
Residence, n (%)				0.98
Urban	1236 (85.6)	528 (85.6)	708 (85.6)	
Rural	208 (14.4)	89 (14.4)	119 (14.4)	
Tuberculosis, n (%)	428 (29.6)	214 (34.7)	214 (27.9)	0.0003
Weight, Kg				<0.0001
< 50, n (%)	308/1322 (23.3)	69/570 (12.1)	239/752 (31.8)	
50-60, n (%)	535/1322 (40.5)	204/570 (35.8)	331/752 (44.0)	
>60, n (%)	479/1322 (36.2)	297/570 (52.1)	182/752 (24.2)	
Median (25 <sup>th</sup> -75 <sup>th</sup> percentile)	57 (50 - 65)	61 (54-68)	54 (47.5-60)	<0.0001
WHO stage, n (%)				0.82
I and II	186/1295 (14.4)	78/553 (14.1)	108/742 (14.6)	
III and IV	1109/1295 (85.6)	475/553 (85.9)	634/742 (85.4)	
Platelets, X1000/mm <sup>3</sup>	244 (180– 320)	229 (173-309)	259 (190-330)	0.0005
Total lymphocytes, X10/mm <sup>3</sup>	130 (90–190)	130 (90-201)	130 (90-190)	0.88
CD4, /mm <sup>3</sup>				0.21
< 50, n (%)	468 (32.4)	216 (30.5)	256 (30.5)	
50-99, n (%)	257 (17.8)	111 (18.0)	142 (17.6)	
100-200, n (%)	562 (38.9)	231 (37.4)	331 (40.0)	
>200, n (%)	157 (10.9)	59 (9.6)	98 (11.8)	
Median (25 <sup>th</sup> -75 <sup>th</sup> percentile)	99 (36.2-161)	89 (33-155)	105 (39-166)	0.018
Haemoglobin, g/dl,				<0.0001
< 8, n (%)	235/1388 (16.9)	67/594 (11.3)	168/794 (21.2)	
8-10, n (%)	506/1388 (36.5)	178/594 (30.0)	328/794 (41.3)	
>10, n (%)	647/1388 (46.6)	349 (58.7)	298 (37.5)	
Median, (25 <sup>th</sup> -75 <sup>th</sup> percentile)	9.9 (8.5-11.2)	10.5 (9-12)	9.5 (8.1-10.7)	<0.0001

NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; WHO, World Health Organisation

\* For all characteristics with missing values, estimates are based of the subset of participants with valid data for each relevant characteristic, and new denominators always provided.



Table 2 Determinants of all-cause mortality among HIV-positive patients started on antiretroviral therapy (n = 1444)

Variable	Age and sex adjusted		Multivariable adjusted	
	Hazard Ratio (95% CI)	p	Hazard Ratio (95% CI)	p
Age, per year	1.01 (0.98-1.03)	0.56	1.01 (0.99-1.03)	0.37
Male sex	1.44 (0.94-2.11)	0.10	2.15 (1.34-3.45)	0.002
Rural residency	1.14 (0.62-2.09)	0.68	-	
Active tuberculosis	1.59 (0.97-2.61)	0.07	2.35 (1.40-3.92)	0.002
WHO stage III-IV	4.57 (1.68-12.47)	0.004	3.63 (1.29-10.24)	0.02
Weight, per kg lower	1.04 (1.02-1.06)	0.0002	1.03 (1.01-1.05)	0.01
Platelet count, per 1000 lower	1.01 (0.99-1.03)	0.53	-	
CD4 count, per 10/mm <sup>3</sup> lower	1.06 (1.02-1.09)	0.003	1.04 (1.01-1.07)	0.02
Haemoglobin, per g/dl lower	1.14 (1.03-1.26)	0.02	1.12 (1.00-1.26)	0.05
AZT based regimens	0.91 (0.51-1.62)	0.76	-	

AZT, zidovudine; CI, confidence interval; WHO, World Health Organisation

1  
2  
3  
4  
5  
6 **Mortality and its determinants among patients infected with HIV-1 on antiretroviral therapy**  
7 **in a referral centre in Yaounde, Cameroon: a retrospective cohort study**  
8

9  
10 **Short title: Determinants of death among patients with HIV infection**

11 Virginie POKA-MAYAP (1), Eric Walter PEFURA-YONE (1, 2), André Pascal KENGNE (3),  
12 Christopher KUABAN (1, 4)  
13

- 14  
15 1) Pneumology Service, Yaounde Jamot Hospital, Cameroon  
16 2) Department of Internal Medicine and Subspecialties, Faculty of Medicine and Biomedical  
17 Sciences, University of Yaounde I, Cameroon  
18 3) South African Medical Research Council & University of Cape Town, Cape Town, South  
19 Africa  
20 4) Faculty of Health Sciences, University of Bamenda, Cameroon  
21  
22  
23  
24

25  
26 **Correspondence to:**

27  
28 Dr Virginie Poka-Mayap,  
29  
30 Yaounde Jamot Hospital,  
31  
32 PO Box 4021-Yaounde, Cameroon  
33  
34 Tel: (237)99253759,  
35  
36 Email: [pokavirginie@yahoo.fr](mailto:pokavirginie@yahoo.fr)  
37

38 **Tables: 2**

39  
40 **Figures: 0**

41  
42 **Online only material: 0**

43  
44 **Word count:** abstract-288; Main text (excluding tables, figures, abstract & references)-3017  
45

46  
47 **References: 19**  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Objectives:** Mortality has decreased in people with human immunodeficiency virus (HIV) infection, subsequent to the improved access to antiretroviral therapy (ART). We assessed the incidence and determinants of mortality among patients with HIV-1 infection, started on ART in a referral treatment centre for HIV infection in Yaounde, Cameroon.

**Design:** Cohort study with baseline assessment between 2007 and 2008, and follow-up during five years until June 2012.

**Setting:** The accredited HIV treatment centre of the Yaounde Jamot Hospital, in capital city of Cameroon.

**Participants:** People living with HIV infection who started ART between 2007 and 2008 at the study centre.

**Outcome measures:** All-cause mortality over time, with the accelerated failure time models were used to relate baseline characteristics with mortality occurrence during follow-up.

**Results:** Of the 1444 patients included, 827 (53.7 %) were men, and the median age (25<sup>th</sup>-75<sup>th</sup> percentiles) was 38 (31- 45) years. The median duration of follow-up was 14.1 (1.1 - 46.4) months, during which 235 deaths were recorded (cumulative incidence rate: 16.3 %), including 208 (88.5 %) during the first year of follow-up. Baseline predictors of mortality were male gender [adjusted hazard ratio 2.15 (95 % Confidence Interval : 1.34 - 3.45)], active tuberculosis [2.35 (1.40 - 3.92)], WHO stages III-IV of the disease [3.63 (1.29 - 10.24)], low weight [1.03 (1.01-1.05) per kilogramme], low CD4 count [1.04 (1.01 - 1.07) per 10/mm<sup>3</sup>] and low haemoglobin levels [1.12 (1.00 - 1.26) per g/dl].

**Conclusions:** Death rate among patients with HIV is very high within the first year of starting ART in this centre. Early start of the treatment, at a less advanced stage of the disease, and much favourable levels of CD4 and other predictors could reduce early mortality, but would have to be tested.

*Word count – 288*

*Key words:* HIV infection, death, determinants, cohort, Cameroon, antiretroviral therapy

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ARTICLE SUMMARY

### Article focus

- To investigate mortality occurrence and determinants among patients with HIV-1 infection, started on antiretroviral therapy in a major reference treatment centre

### Key messages

- Death rate among patients with HIV is very high within the first year of starting antiretroviral therapy in this centre
- Male gender, active tuberculosis, advanced stage of the disease, low CD4 count, low weight and low haemoglobin levels at baseline were significant predictors of all-cause mortality during follow-up

### Strengths and limitations

- Strengths of the study include the large sample size and the use of robust methods to relate baseline predictors to the outcome occurrence during follow-up.
- The study was based on data collected from patient files and clinical registers, and as expected there were missing data, particularly on the true outcome of patients who were lost-to-follow-up.

## INTRODUCTION

Human immunodeficiency virus (HIV) infection is a major global health problem. Sub-Saharan Africa (SSA), with about 68 % of the global population with HIV, is the most affected region in the world. [1] HIV related mortality appears to be higher in developing than in developed countries. [2] Hopefully, mortality rates are on the decline with the improved access to antiretroviral therapy (ART), [3] while explaining factors of the residual deaths seems to vary significantly across populations. Studies in SSA have found that mortality rate is particularly high during the first year of starting antiretroviral therapy, [4] with male sex, cachexia, advanced stage of the disease, low CD4 count, anaemia, high viral load at baseline, and poor adherence to treatments being the main determinants of death. [5-8]

In Cameroon, about 105,000 people living with HIV (PLHIV) infection were on ART by the end of the year 2011, [9] A study conducted in 2006 in a rural unit for HIV treatment in the northern part of the country, found a mortality rate of 20.2/100 person-years among HIV patients receiving ART. [10] This figure however, has not been updated since 2007, year of the introduction of free access to ART in the country. Thus, the aim of this study was to determine the mortality rate and its determinants among patients with HIV-1 infection, started on ART in a reference treatment centre in Cameroon.

## PARTICIPANTS AND METHODS

### Study setting

The study was conducted in the accredited HIV treatment centre (ATC) of the Yaounde Jamot Hospital (YJH) in the Capital city of Cameroon. The study setting has been described in detail previously elsewhere. [11, 12] In brief, YJH is the referral centre for tuberculosis and chest diseases for the Capital city (Yaounde) and surrounding areas. It has an ATC that provides care to PLHIV. As of June 2011, a total of 2250 PLHIV were followed in the centre.

### Care of patients with HIV infection

During the study period, PLHIV were started on ART in the presence of a CD4 count below 200/mm<sup>3</sup> or superimposed condition of the WHO stage IV of the disease severity other than tuberculosis. [13] Patients fulfilling these criteria were referred to the ATC for treatment inception and follow-up. A medical file was created under the supervision of the attending physician and included socio demographic, clinical and biological data of the patient. Files of eligible patients were presented at weekly meetings during which the appropriate treatment regimen for each patient

1  
2  
3  
4  
5  
6 was decided. First line treatment regimens included two nucleoside reverse transcriptase inhibitors  
7 (zidovudine, lamivudine, tenofovir) and one non-nucleoside reverse transcriptase inhibitor  
8 (nevirapine or efavirenz). Second line regimens comprised two nucleoside reverse transcriptase  
9 inhibitors (zidovudine, didanosine, lamivudine, tenofovir) and a protease inhibitor (indinavir,  
10 lopinavir/ritonavir). These regimens were all dispensed to patients free of charge and they were all  
11 started on prophylactic treatment with cotrimoxazole. All patients had a session with trained  
12 psychosocial advisors, to improve adherence to prescribed therapies.  
13  
14  
15

16 Patients registered at the YJH's ATC are seen on a monthly basis for prescription renewal.  
17 For those on a regimen comprising zidovudine (AZT) and/or nevirapine (NVP), haemoglobin  
18 (AZT) and/or liver transaminases (NVP) levels are monitored at two weeks from starting treatment.  
19 A biological profile is requested every six months, comprising a CD4 count, full blood count, liver  
20 transaminases and creatinin (only for patients receiving tenofovir), and results are recorded in the  
21 clinical file.  
22  
23  
24

## 25 Outcome

26  
27 During the study period, patients who failed to report for consultation for three consecutive  
28 months were traced by community liaison agents using the contact details on the file. All-cause  
29 mortality was considered for all deceased patients at any time after starting ART. The time-to-death  
30 (in months) was the interval from the start of the ART to date of death (or date of the last recorded  
31 visit when the date of death was unknown). Loss-to-follow-up (defaulter) was defined as patients  
32 who failed to return for consultation for three consecutive months and were unsuccessfully traced  
33 by liaison agents, [14] Transfer was considered for patients who at any time were definitively  
34 transferred to receive care in another centre. The follow-up for all patients was until June 2012,  
35 death, transfer and loss to follow-up, whichever came first.  
36  
37  
38  
39  
40

## 41 Data collection

42  
43 For the purpose of this study, patients with HIV started on ART between January 2007 and  
44 December 2008 were identified via antiretroviral treatment registries. All patients with HIV-1  
45 infection, aged 18 years and above, started on ART during this period were included in the study,  
46 and followed until June 2012 (5.5 years). The study was approved by the regulatory board of YJH.  
47  
48  
49

50 The following data were then retrieved in the medical files of eligible patients: sex, baseline  
51 age (in years), residence (urban vs. rural), weight in Kg, presence of opportunistic infection, CD4  
52 count (in cells/mm<sup>3</sup>), haemoglobin levels in g/dl, total lymphocytes and platelet counts,  
53 antiretroviral regimens; outcome (death, loss to follow up, transfer out, still alive and followed up),  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 and estimated time to the outcome occurrence in months. The duration of follow-up for patients still  
7 actively followed-up was censored in June 2012.  
8

### 9 10 **Statistical analysis**

11  
12 Data analysis used SPSS v17.0 (SPSS Inc., Chicago, USA) and SAS/STAT® v 9.1 for  
13 Windows (SAS Institute Inc., Cary, NC, USA). Results are presented as count and percentages,  
14 mean and standard deviation or median and 25<sup>th</sup>-75<sup>th</sup> percentiles. The chi square test, Student's t-  
15 test and their non-parametric equivalents were used to compare baseline characteristics. The  
16 Kaplan-Meier estimator and accelerated failure time models, implemented with the use of  
17 LIFETEST and LIFEREG procedures of SAS were used to investigate the baseline characteristics  
18 associated with mortality during the first 60 months of follow-up (corresponding to the observed  
19 duration of follow-up for > 95% of participants). Candidate predictors included age (in years),  
20 gender (male vs. female), residency (rural vs. urban), active tuberculosis, WHO stages of the  
21 disease (III-IV vs. I-II), weight (in kg), platelet count (per 1000), CD4 count (per 10/mm<sup>3</sup>),  
22 haemoglobin level (in g/dl) and ART regimen (AZT vs. no AZT). Candidate predictors were tested  
23 one at a time in a basic model that included gender and age as covariates. Then significant  
24 predictors (based on a p-value <0.10) were entered together in a multivariable model, and  
25 significant ones kept in the final model alongside age and gender. The reference category (or  
26 direction of continuous predictors) was always rearranged as appropriate to identify levels  
27 associated with increased mortality risk. A p-value < 0.05 was used to characterise statistically  
28 significant results.  
29  
30  
31  
32  
33  
34  
35

## 36 **RESULTS**

### 37 **Data available**

38  
39 In 2007 and 2008, a total of 1444 PLHIV [including 827 women (57.3 %)] were started on ART at  
40 the YJH's ATC. Medical files were available for all of them. However, data were missing on some  
41 characteristics for few participants. Analyses for those characteristics are restricted to participants  
42 with valid data, and their number indicated where relevant. Furthermore, a total of 470 participants  
43 had missing data for at least one of the candidate predictors, and were therefore excluded from  
44 regression analysis. Compared with excluded participants, the 974 included in regression analysis  
45 had similar age (38.3 vs. 38.8 years, p = 0.44), mean CD4 count (102 vs. 111/mm<sup>3</sup>, p = 0.06).  
46 Furthermore, they had similar proportion of men (42.5 % vs. 43.2 %, p = 0.82), similar distribution  
47 across WHO stages of disease severity (p = 0.75), a borderline higher prevalence of active  
48 tuberculosis (31.1% vs. 26.6%, p = 0.044), a borderline lower baseline weight (57.6 vs. 59.1 kg,  
49  
50  
51  
52  
53  
54

p=0.045) and lower platelet (262000 vs. 243000/mm<sup>3</sup>, p = 0.035), and a significantly lower haemoglobin level (9.9 vs. 10.4 g/dl, p < 0.001).

### Baseline characteristics of the study population

The baseline demographic, clinical and biological characteristics of participants are summarised in Table 1. The median age (25<sup>th</sup>-75<sup>th</sup> percentiles) was 38 (31 - 45) years overall, 40 (34 - 47) years in men and 35 (30 - 43) years in women, p < 0.0001. In all 85.6 % of participants were urban dwellers and about the same proportion were started on ART at WHO stage III-IV of disease severity, similarly among men and women (both p ≥ 0.82, Table 1). The main opportunistic infection was tuberculosis, which was found in 428 (29.6 %) patients, and was more frequent in men than in women (34.7 % vs. 27.9 %, p = 0.0003). The median CD4 count (25<sup>th</sup> - 75<sup>th</sup> percentiles) was 99 (36 - 161) per mm<sup>3</sup> overall, 89 (33 - 155) in men and 105 (39 - 166) in women (p = 0.018).

### Follow-up and outcome

The median duration of follow-up (25<sup>th</sup> - 75<sup>th</sup> percentiles) was 14.4 (1.0 - 46.2) months overall, 9.1 (0 - 44.1) months in men and 20.3 (1.3 - 47.3) months in women (p < 0.0001). At the final evaluation, 235 (cumulative incidence rate 16.3 %) were deceased, 590 (40.8 %) were lost to follow-up, 173 (12 %) had been transferred to another centre, while 446 patients (30.9 %) were still under active follow-up in the centre. The median duration of follow-up (25<sup>th</sup> - 75<sup>th</sup> percentiles) for non-fatal outcomes was 4.5 (0 - 23.8) months for defaulters, 8.2 (2.5 - 20.3) months for transfer out, and 50.5 (45.9 - 56.7) months for active follow-up cases.

Of the 235 deaths recorded, 208 (88.5 %) deaths occurred early (within the first year of ART) while 27 (11.5 %) were late-occurring deaths. Overall, 54.9 % of all deaths occurred within one month of starting antiretroviral therapy, 19.6 % between 1 and 3 months, 8.5 % between 3 and 6 months and 5.5% between 6 and 12 months. The cumulative survival probability from Kaplan-Meier estimators was 84.7 % (95 % confidence interval: 82.7 - 86.7) at 6 months, 83.3 % (81.3 - 85.4) at 12 months, 81.7 % (79.5 - 83.9) at 24 months, and 79.3% (76.0 - 82.5) at 60 months of follow-up. The survival probability from Kaplan-Meier estimators and Weibull plot of the cumulative distribution function for all-cause mortality are depicted in Figure 1. **The cumulative mortality rate was 16.8 % (79/470) among participants with missing data on at least one of the candidate predictor variables, and 16.6 % (162/974) among those with valid data, p = 0.93.**



## Determinants of all-cause mortality

The estimated cumulative distribution function for all-cause mortality by major subgroups is depicted in figure 2. In sex and age adjusted analyses, male sex, active tuberculosis, WHO stage III-IV of the disease, lower weight, lower CD4 count and lower baseline haemoglobin level were potential determinants of all-cause mortality (Table 2). In multivariable Weibull regression models with simultaneous adjustment for age, sex, and all the potential factors, all determinants remained significantly associated with all-cause mortality during follow-up (Table 2). Effect estimates (hazard ratio) and 95% confidence intervals were 2.15 (1.34 - 3.45) for male sex, 2.35 (1.40 - 3.92) for active tuberculosis, 3.63 (1.29 - 10.24) for WHO stage III-IV of the disease severity, 1.03 (1.01 - 1.05) per kilogram lower weight, 1.04 (1.01 - 1.07) per 10 lower CD4/mm<sup>3</sup> and 1.12 (1.00 - 1.26) for each g/dl lower baseline haemoglobin (Table 2).

## DISCUSSION

This study conducted in a referral centre for tuberculosis and HIV care in Cameroon revealed a high mortality rate among patients started on ART, with the large majority of death occurring during the first year of starting the treatment. Male gender, active tuberculosis, advanced stage of the disease, low CD4 count, low weight and low haemoglobin levels at baseline were significant predictors of all-cause mortality during follow-up. Accounting for these factors may help in refining the prescription of ART and improve the outcome of care among patients with HIV infection.

The survival probability at one year of follow-up after starting ART was found to be much lower (83.3 % vs. 77 %) than in a previous study among 1187 PLHIV infection in a rural setting in the Northern part of Cameroon. [10] This study however, was conducted prior 2007, year of the implementation of the program of free access to ART in the country, which suggests that this strategy has likely improved survival among PLHIV in the country. It can also be speculated that the difference between this previous study and our study just reflects differences in the level of care provided in a referral centre like ours, and a rural centre where care can be very basic. The similarities in the baseline profile of participants across the two studies are in support of this hypothesis. For instance, in both studies over 85 % of participants were started on ART while at the WHO stage III or IV of the disease severity, while pre-ARV CD4 count was lower than 50/mm<sup>3</sup> in over a quarter of participants at baseline. However, the one-year survival rate in our study is within the range of those reported in previous studies. In recent meta-analysis of those studies, the pooled estimated one-year probability of death from studies conducted in Africa was 17 % (95 % confidence interval: 11-24 %), [6, 15]

1  
2  
3  
4  
5  
6 Predictors of mortality identified in our study were essentially those described in existing  
7 reports. [6, 15] The adverse profile of modifiable risk factors clearly suggests that patients with HIV  
8 in our centre are started on ART at an advanced stage of the disease. This likely reflects the fact that  
9 in this setting, with the exception of screening in particular circumstances such as during pregnancy  
10 or pre-surgical intervention, PLHIV mostly get screened only when they seek medical care with  
11 clinical symptoms. This is a common attitude across Africa, which may explain the higher early  
12 mortality rate on ART in Africa, compared with other parts of the world.[6] In addition to the  
13 advanced clinical stage of the disease on the WHO scale at presentation, body weight, CD4 count  
14 and haemoglobin levels were low at baseline, and all significantly associated with high risk of  
15 mortality during follow-up as previously reported. [5-8] It is of note that at the time this study was  
16 conducted, most patients were started on ART at CD4 count below 200/mm<sup>3</sup>. Recent WHO  
17 recommendations favour ART initiation at CD4 count below 350/mm<sup>3</sup>. Their uptake may  
18 potentially reduce early mortality rate, as a result of many patients starting treatment at favourable  
19 CD4 levels. The prevalence of active tuberculosis in our study was possibly inflated by the nature  
20 of the study setting as a referral centre for tuberculosis treatment, where most patients with both  
21 HIV and tuberculosis are likely to be referred for care. The resulting subsample of participants with  
22 both conditions has possibly increased our statistical power for uncovering baseline active  
23 tuberculosis as a risk factor for mortality among PLHIV started on antiretroviral therapy. Such an  
24 association has been inconsistently reported in previous studies. [6, 10, 16]

25  
26  
27  
28  
29  
30  
31  
32  
33  
34 Free access to ART was introduced in Cameroon in May 2007 [17]. We have recently reported rate  
35 of non-adherence to ART to be as high as 34 % among patients with HIV receiving chronic care at the YJH  
36 in the era of free access to ART [12]. In the absence of any assessment of the adherence to ART in the  
37 current study, it is difficult to speculate of a contribution, if any, of non-adherence to ART to the observed  
38 high mortality in our study. However, such an effect is likely marginal in this setting where mortality mostly  
39 occurs early when patients have not been exposed to ART enough to derive therapeutic benefits.  
40 Furthermore, existing instruments for measuring adherence to ART are likely unsuitable for investigating  
41 premature mortality risk. The main non-modifiable risk factor of mortality in our study was male sex.  
42 This was not fully explained by sex differences in the level of other risk factors. Indeed, with the  
43 exception of baseline CD4 count which was lower in men, other factors were equally distributed  
44 among men or women or rather showed more favourable levels in men. Other studies have shown  
45 that adherence to prescribed ART was better in women than in men, [18] which can explain  
46 differing rates of mortality between men and women started on ART.

47  
48  
49  
50 Our study has some limitations, including the missing data, which are expected for a study  
51 conducted based on data collected from patients files, and when dealing with large numbers of

Comment [DP1]:

1  
2  
3  
4  
5  
6 participants. Drop-out through losses to follow-up potentially include deceased patients, and may be  
7 in high proportion based on some studies. [19] Therefore, the reported mortality rate in our study is  
8 likely underestimated. But such a bias is unlikely to affect the associations of major risk factors  
9 with the mortality outcome as shown elsewhere. [10] In the absence of any evaluation of the  
10 adherence to ART, particularly among early mortality survivors, we were unable to investigate a  
11 potential effect of non-adherence to ART on mortality risk in the current study. Our study also has  
12 major strengths including the large sample size, which increased our statistical power to reliably  
13 characterise the predictors of mortality. The death rate following ART initiation as found in our  
14 study and other published studies is not constant over time. It is very high in the early months of  
15 starting the treatment, and subsequently drops and stabilises at a much lower rate. Many previous  
16 studies have been based on statistical methods that assume constant death rates over time such as  
17 the person-year methods, and have likely generated less reliable estimates of the association of  
18 predictors with mortality risk. We have attempted to address this limitation by applying the  
19 accelerated failure time models in our study. Unlike Cox models for instance, regression parameters  
20 estimates from accelerated failure time models are robust to the omitted covariates, and are  
21 unaffected by the choice of probability distribution.  
22  
23  
24  
25  
26  
27  
28

29  
30 In conclusion, mortality rate among patients with HIV-1 infection started on antiretroviral  
31 therapy in this setting remain unacceptably high. Deaths occur mostly within the first year of  
32 starting treatment and essentially among patients with clinical and biological profiles compatible  
33 with an advanced stage of the disease at the time when antiretroviral treatment is started. Strategies  
34 for early detection of patient with HIV and the clinically asymptomatic stages followed by early  
35 initiation of antiretroviral therapy needs to be developed and tested in this setting. Recent  
36 Cameroonian guidelines of HIV treatment allowing the prescription of antiretroviral therapy to  
37 patients with CD4 count lower than  $350/\text{mm}^3$  would probably reduce the mortality rate in this  
38 setting.  
39  
40  
41  
42

43 **Funding:** This research received no specific grant from any funding agency in the public,  
44 commercial or not-for-profit sectors.  
45

46 **Competing interests:** None.  
47

48 **Ethics approval:** Ethics approval was provided by the Institutional Review Board of Yaounde  
49 Jamot Hospital.  
50

51 **Contributors:** VPM, collected data, co-analysed the data and drafted the manuscript. EWPY  
52 conceived the study, supervised data collection, co-analysed the data and drafted the manuscript.  
53  
54

1  
2  
3  
4  
5  
6 APK contributed to study design, data analysis, drafting and critical revision of the manuscript. CK  
7 supervised data collection and critically revised the manuscript. All authors approved the final  
8 version of the manuscript.  
9

## 10 11 12 13 REFERENCES

- 14  
15 1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Report on the global AIDS  
16 epidemic. 2012  
17 [http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120\\_UNAIDS\\_Global\\_Report\\_2012\\_en.pdf](http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_UNAIDS_Global_Report_2012_en.pdf) (Accessed 6 May 2013)
- 18  
19 2. Braitstein P, Brinkhof MW, Dabis F *et al*. Mortality of HIV-1-infected patients in the first  
20 year of antiretroviral therapy: comparison between low-income and high-income countries.  
21 *Lancet* 2006;**367**:817-824.
- 22  
23 3. Palella FJ, Baker RK, Moorman AC *et al*. Mortality in the highly active antiretroviral  
24 therapy era: changing causes of death and disease in the HIV outpatient study. *J Acquir  
25 Immune Defic Syndr* 2006;**43**:27-34.
- 26  
27 4. Marazzi MC, Liotta G, Germano P *et al*. Excessive early mortality in the first year of  
28 treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited  
29 settings. *AIDS Res Hum Retroviruses* 2008;**24**:555-560.
- 30  
31 5. Kouanda S, Meda IB, Nikiema L *et al*. Determinants and causes of mortality in HIV-  
32 infected patients receiving antiretroviral therapy in Burkina Faso: a five-year retrospective  
33 cohort study. *AIDS Care* 2012;**24**:478-90.
- 34  
35 6. Gupta A, Nadkarni G, Yang WT *et al*. Early mortality in adults initiating antiretroviral  
36 therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-  
37 analysis. *PLoS One* 2011;**6**:e28691.
- 38  
39 7. Fregonese F, Collins IJ, Jourdain G *et al*. Predictors of 5-years mortality in HIV-infected  
40 adults starting highly active antiretroviral therapy (HAART) in Thailand. *J Acquir Immune  
41 Defic Syndr* 2012;**60**:91-8.
- 42  
43 8. Laurent C, Meilo H, Guiard-Schmid JB *et al*. Antiretroviral therapy in public and private  
44 routine health care clinics in Cameroon: lessons from the Douala antiretroviral (DARVIR)  
45 initiative. *Clin Infect Dis* 2005;**41**:108-111.
- 46  
47 9. Ministère de la Santé Publique. Rapport national de suivi de la déclaration politique sur le  
48 VIH/SIDA Cameroun 2012.  
49  
50  
51  
52  
53  
54

10. Sieleunou I, Souleymanou M, Schonenberger AM et al. Determinants of survival in AIDS patients on antiretroviral therapy in a rural centre in the Far-North Province, Cameroon. *Trop Med Int Health* 2009;**14**:36-43.
11. Pefura Yone EW, Betyoumin AF, Kengne AP et al. First-line antiretroviral therapy and dyslipidemia in people living with HIV-1 in Cameroon: a cross-sectional study. *AIDS Res Ther* 2011;**8**:33.
12. Pefura Yone EW, Soh E, Kengne AP et al. Non-adherence to antiretroviral therapy in Yaounde: Prevalence, determinants and the concordance of two screening criteria. *Journal of Infection and Public Health* 2013. doi:10.1016/j.jiph.2013.02.003.
13. Ministère de la Santé Publique du Cameroun. Directives nationales de prise en charge par les antirétroviraux des personnes (adultes et adolescents) infectés par le VIH. Yaoundé 2007.
14. Wools-Kaloustian K, Kimaiyo S, Diero L et al. Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. *Aids* 2006;**20**:41-48.
15. Biadgilign S, Reda AA, Digaffe T. Predictors of mortality among HIV infected patients taking antiretroviral treatment in Ethiopia: a retrospective cohort study. *AIDS Res Ther* 2012;**9**:15.
16. Amuron B, Levin J, Birunghi Jet al. Mortality in an antiretroviral therapy programme in Jinja, south-east Uganda: a prospective cohort study. *AIDS Res Ther* 2011;**8**:39.
17. Ministry of Public Health, Republic of Cameroon. National AIDS Control Committee: Towards universal access to care and treatment for adults and children living with HIV/AIDS in Cameroon. Progress Report N° 4. 2006.
18. MacPherson P, Moshabela M, Martinson N et al. Mortality and loss to follow-up among HAART initiators in rural South Africa. *Trans R Soc Trop Med Hyg* 2009, **103**:588-593.
19. Yu JK, Chen SC, Wang KY et al. True outcomes for patients on antiretroviral therapy who are "lost to follow-up" in Malawi. *Bull World Health Organ* 2007;**85**:550-554.

Table 1 Demographic, clinical and biological profile of HIV patients started on antiretroviral therapy at the Yaounde Jamot Hospital in 2007 and 2008

Characteristics*	Overall	Men	Women	p-value
n	1444	617	827	
Median age, years (25 <sup>th</sup> -75 <sup>th</sup> percentile)	38 (31-45)	40 (34-47)	35 (30-43)	<0.0001
Residence, n (%)				0.98
Urban	1236 (85.6)	528 (85.6)	708 (85.6)	
Rural	208 (14.4)	89 (14.4)	119 (14.4)	
Tuberculosis, n (%)	428 (29.6)	214 (34.7)	214 (27.9)	0.0003
Weight, Kg				<0.0001
< 50, n (%)	308/1322 (23.3)	69/570 (12.1)	239/752 (31.8)	
50-60, n (%)	535/1322 (40.5)	204/570 (35.8)	331/752 (44.0)	
>60, n (%)	479/1322 (36.2)	297/570 (52.1)	182/752 (24.2)	
Median (25 <sup>th</sup> -75 <sup>th</sup> percentile)	57 (50 - 65)	61 (54-68)	54 (47.5-60)	<0.0001
WHO stage, n (%)				0.82
I and II	186/1295 (14.4)	78/553 (14.1)	108/742 (14.6)	
III and IV	1109/1295 (85.6)	475/553 (85.9)	634/742 (85.4)	
Platelets, X1000/mm <sup>3</sup>	244 (180- 320)	229 (173-309)	259 (190-330)	0,0005
Total lymphocytes, X10/mm <sup>3</sup>	130 (90-190)	130 (90-201)	130 (90-190)	0.88
CD4, /mm <sup>3</sup>				0.21
< 50, n (%)	468 (32.4)	216 (30.5)	256 (30.5)	
50-99, n (%)	257 (17.8)	111 (18.0)	142 (17.6)	
100-200, n (%)	562 (38.9)	231 (37.4)	331 (40.0)	
>200, n (%)	157 (10.9)	59 (9.6)	98 (11.8)	
Median (25 <sup>th</sup> -75 <sup>th</sup> percentile)	99 (36.2-161)	89 (33-155)	105 (39-166)	0.018
Haemoglobin, g/dl,				<0.0001
< 8, n (%)	235/1388 (16.9)	67/594 (11.3)	168/794 (21.2)	
8-10, n (%)	506/1388 (36.5)	178/594 (30.0)	328/794 (41.3)	
>10, n (%)	647/1388 (46.6)	349 (58.7)	298 (37.5)	
Median, (25 <sup>th</sup> -75 <sup>th</sup> percentile)	9.9 (8.5-11.2)	10.5 (9-12)	9.5 (8.1-10.7)	<0.0001

NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; WHO, World Health Organisation

\* For all characteristics with missing values, estimates are based of the subset of participants with valid data for each relevant characteristic, and new denominators always provided.

Table 2 Determinants of all-cause mortality among HIV-positive patients started on antiretroviral therapy (n = 1444)

Variable	Age and sex adjusted		Multivariable adjusted	
	Hazard Ratio (95% CI)	p	Hazard Ratio (95% CI)	p
Age, per year	1.01 (0.98-1.03)	0.56	1.01 (0.99-1.03)	0.37
Male sex	1.44 (0.94-2.11)	0.10	2.15 (1.34-3.45)	0.002
Rural residency	1.14 (0.62-2.09)	0.68	-	
Active tuberculosis	1.59 (0.97-2.61)	0.07	2.35 (1.40-3.92)	0.002
WHO stage III-IV	4.57 (1.68-12.47)	0.004	3.63 (1.29-10.24)	0.02
Weight, per kg lower	1.04 (1.02-1.06)	0.0002	1.03 (1.01-1.05)	0.01
Platelet count, per 1000 lower	1.01 (0.99-1.03)	0.53	-	
CD4 count, per 10/mm <sup>3</sup> lower	1.06 (1.02-1.09)	0.003	1.04 (1.01-1.07)	0.02
Haemoglobin, per g/dl lower	1.14 (1.03-1.26)	0.02	1.12 (1.00-1.26)	0.05
AZT based regimens	0.91 (0.51-1.62)	0.76	-	

AZT, zidovudine; CI, confidence interval; WHO, World Health Organisation



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 2: Estimated cumulative distribution function for all-cause mortality by major subgroups among patients with HIV infection who started antiretroviral treatment at the Yaounde Jamot Hospital in 2007 and 2008  
297x209mm (300 x 300 DPI)

Review only




Figure 1: Survival probability from Kaplan-Meier estimator (upper panel) and Weibull plot showing the cumulative distribution function for mortality during follow-up of patients with HIV infection who started antiretroviral treatment at the Yaounde Jamot Hospital in 2007 and 2008  
297x209mm (300 x 300 DPI)



**Mortality and its determinants among patients infected with HIV-1 on antiretroviral therapy in a referral centre in Yaounde, Cameroon: a retrospective cohort study**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-003210.R2
Article Type:	Research
Date Submitted by the Author:	06-Jun-2013
Complete List of Authors:	Poka-Mayap, Virginie; Yaounde Jamot Hospital, Pneumology Service Pefura-Yone, Eric Walter; Yaounde Jamot Hospital, Pneumology Service; Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Department of Internal Medicine and Subspecialties Kengne, Andre; South African Medical Research Council, Kuaban, Christopher; Faculty of Health Sciences, University of Bamenda, ; Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Department of Internal Medicine and Subspecialties
<b>Primary Subject Heading</b>:	HIV/AIDS
Secondary Subject Heading:	Epidemiology
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, Epidemiology < INFECTIOUS DISEASES, EPIDEMIOLOGY

SCHOLARONE™  
Manuscripts

only

1  
2 **Mortality and its determinants among patients infected with HIV-1 on antiretroviral therapy**  
3 **in a referral centre in Yaounde, Cameroon: a retrospective cohort study**  
4

5  
6 **Short title: Determinants of death among patients with HIV infection**  
7

8 Virginie POKA-MAYAP (1), Eric Walter PEFURA-YONE (1, 2), André Pascal KENGNE (3),  
9 Christopher KUABAN (1, 4)  
10

- 11  
12 1) Pneumology Service, Yaounde Jamot Hospital, Cameroon  
13  
14 2) Department of Internal Medicine and Subspecialties, Faculty of Medicine and Biomedical  
15 Sciences, University of Yaounde I, Cameroon  
16  
17 3) South African Medical Research Council & University of Cape Town, Cape Town, South  
18 Africa  
19  
20 4) Faculty of Health Sciences, University of Bamenda, Cameroon  
21  
22  
23  
24

25 **Correspondence to:**  
26

27 Dr Virginie Poka-Mayap,  
28  
29 Yaounde Jamot Hospital,  
30  
31 PO Box 4021-Yaounde, Cameroon  
32  
33  
34  
35 Tel: (237)99253759,  
36  
37 Email: [pokavirginie@yahoo.fr](mailto:pokavirginie@yahoo.fr)  
38  
39

40 **Tables: 2**  
41

42 **Figures: 0**  
43

44 **Online only material: 0**  
45

46  
47 **Word count:** abstract-270; Main text (excluding tables, figures, abstract & references)-2933  
48

49 **References: 19**  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**ABSTRACT**

**Objectives:** Mortality has declined in people with human immunodeficiency virus (HIV) infection, subsequent to the improved access to antiretroviral therapy (ART). We assessed the incidence and determinants of mortality among patients with HIV-1 infection, started on ART in a referral treatment centre for HIV infection in Yaounde, Cameroon.

**Design:** Cohort study with baseline assessment between 2007 and 2008, and follow-up during five years until June 2012.

**Setting:** The accredited HIV treatment centre of the Yaounde Jamot Hospital, in capital city of Cameroon.

**Participants:** People living with HIV infection who started ART between 2007 and 2008 at the study centre.

**Outcome measures:** All-cause mortality over time; accelerated failure time models used to relate baseline characteristics to mortality occurrence during follow-up.

**Results:** Of the 1444 patients included, 827 (53.7%) were men, and the median age (25<sup>th</sup>-75<sup>th</sup> percentiles) was 38 (31-45) years. The median duration of follow-up was 14.1 (1.1-46.4) months, during which 235 deaths were recorded (cumulative incidence rate: 16.3%), including 208 (88.5%) during the first year of follow-up. Baseline predictors of mortality were male gender [adjusted hazard ratio 2.15 (95% confidence interval : 1.34-3.45)], active tuberculosis [2.35 (1.40-3.92)], WHO stages III-IV of the disease [3.63 (1.29-10.24)], low weight [1.03 (1.01-1.05) per kilogramme], low CD4 count [1.04 (1.01-1.07) per 10/mm<sup>3</sup> lower CD4] and low haemoglobin levels [1.12 (1.00-1.26) per g/dl lower].

**Conclusions:** Mortality rate among patients with HIV is very high within the first year of starting ART in this centre. Early start of the treatment, at a less advanced stage of the disease, and favourable levels of CD4 and other predictors could reduce early mortality, but would have to be tested.

*Word count – 270*

*Key words:* HIV infection, mortality, determinants, cohort, Cameroon, antiretroviral therapy

## ARTICLE SUMMARY

### Article focus

- To investigate mortality occurrence and determinants among patients with HIV-1 infection, started on antiretroviral therapy in a major reference treatment centre

### Key messages

- Mortality rate among patients with HIV is very high, particularly within the first year of starting antiretroviral therapy in this centre
- Male gender, active tuberculosis, advanced stage of the disease, low CD4 count, low weight and low haemoglobin levels at baseline were significant predictors of all-cause mortality during follow-up

### Strengths and limitations

- Strengths of the study include the large sample size and the use of robust methods to relate baseline predictors to the mortality occurrence during follow-up.
- The study was based on data collected from patient files and clinical registers, and as expected there were missing data, particularly on the true outcome of patients who were lost-to-follow-up.

## INTRODUCTION

Human immunodeficiency virus (HIV) infection is a major global health problem. Sub-Saharan Africa (SSA), with about 68% of the global population with HIV, is the most affected region in the world.[1] HIV related mortality appears to be higher in developing than in developed countries.[2] Hopefully, mortality rates are declining with the improved access to antiretroviral therapy (ART),[3] while explaining factors for the residual deaths seem to vary significantly across populations. Studies in SSA have found that mortality rate is particularly high during the first year of starting ART,[4] with male sex, cachexia, advanced stage of the disease, low CD4 count, anaemia, high viral load at baseline, and poor adherence to treatments being the main determinants of mortality.[5-8]

In Cameroon, about 105,000 people living with HIV (PLHIV) infection were on ART by the end of the year 2011.[9] A study conducted in 2006 in a rural unit for HIV treatment in the northern part of the country, found a mortality rate of 20.2/100 person-years among HIV patients receiving ART.[10] This figure however, has not been updated since 2007, the year of introduction of free access to ART in the country. Thus, the aim of this study was to determine the mortality rate and determinants among patients with HIV-1 infection, started on ART in a reference treatment centre in Cameroon.

## PARTICIPANTS AND METHODS

### Study setting and participants

The study was conducted in the accredited HIV treatment centre (ATC) of the Yaounde Jamot Hospital (YJH) in the capital city of Cameroon. The study setting has been described in details previously.[11,12] In brief, YJH is the referral centre for tuberculosis and chest diseases for the Capital city (Yaounde) and surrounding areas. It has an ATC that provides care to PLHIV. As of June 2011, a total of 2,250 PLHIV were followed in the centre. Patients received at ATC between January 2007 and December 2008, aged 18 years and above, and who were started on ART, were included in the study.

During the study period, PLHIV were started on ART in the presence of a CD4 count below  $200/\text{mm}^3$  or superimposed conditions other than tuberculosis, compatible with the WHO stage IV of the disease severity.[13] Patients fulfilling these criteria were referred to the ATC for treatment inception and follow-up. A medical file was created under the supervision of the attending physician and included socio-demographic, clinical and biological data of the patient. Files of eligible patients were presented at weekly meetings during which the appropriate treatment regimen



1 was decided. First line treatment regimens included two nucleoside reverse transcriptase inhibitors  
2 (zidovudine, lamivudine, tenofovir) and one non-nucleoside reverse transcriptase inhibitor  
3 (nevirapine or efavirenz). Second line regimens comprised two nucleoside reverse transcriptase  
4 inhibitors (zidovudine, didanosine, lamivudine, tenofovir) and a protease inhibitor (indinavir,  
5 lopinavir/ritonavir). These regimens were all dispensed to patients free of charge and they were all  
6 started on prophylactic treatment with cotrimoxazole. All patients had an interaction session with  
7 trained psychosocial advisors, to improve adherence to prescribed therapies.  
8  
9

10 Patients registered at the YJH's ATC are seen on a monthly basis for prescription renewal.  
11 For those on a regimen comprising zidovudine (AZT) and/or nevirapine (NVP), haemoglobin  
12 (AZT) and/or liver transaminases (NVP) levels are monitored at two weeks from starting treatment.  
13 A biological profile is requested every six months, comprising a CD4 count, full blood count, liver  
14 transaminases and creatinin (only for patients receiving tenofovir), and results are recorded in the  
15 clinical files.  
16  
17

### 18 **Outcome**

19 During the study period, patients who failed to report for consultation for three consecutive  
20 months were traced by community liaison agents using the contact details on the file. All-cause  
21 mortality was considered for all deceased patients at any time after starting ART. The time-to-death  
22 (in months) was the interval from the start of the ART to date of death (or date of the last recorded  
23 visit when the date of death was unknown). Loss-to-follow-up (defaulter) was defined as a patient  
24 who failed to return for consultation for three consecutive months and was unsuccessfully traced by  
25 liaison agents.[14] Transfer was considered for patients who at any time were definitively  
26 transferred to receive care in another centre. The follow-up for all patients was until June 2012,  
27 death, transfer and loss to follow-up, whichever came first.  
28  
29

### 30 **Data collection**

31 For the purpose of this study, patients with HIV started on ART during the study period  
32 were identified via antiretroviral treatment registries. All patients with HIV-1 infection, aged 18  
33 years and above, started on ART during this period were included in the study, and followed until  
34 June 2012. The study was approved by the regulatory board of YJH.  
35  
36

37 The following data were retrieved in the medical files of eligible patients: sex, baseline age  
38 (in years), residence (urban vs. rural), weight in Kg, presence of opportunistic infection, CD4 count  
39 (in cells/mm<sup>3</sup>), haemoglobin levels in g/dl, total lymphocytes and platelet counts, antiretroviral  
40 regimens; outcome (death, loss-to-follow-up, transfer out, still alive and followed-up), and  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

estimated time to the outcome occurrence in months. The duration of follow-up for patients still actively followed-up was censored in June 2012.

### Statistical analysis

Data analysis used SPSS v17.0 (SPSS Inc., Chicago, USA) and SAS/STAT® v 9.1 for Windows (SAS Institute Inc., Cary, NC, USA). Results are presented as count and percentages, mean and standard deviation or median and 25<sup>th</sup>-75<sup>th</sup> percentiles. The chi square test, Student's t-test and their non-parametric equivalents were used to compare baseline characteristics. The Kaplan-Meier estimator and accelerated failure time models, implemented with the use of LIFETEST and LIFEREG procedures of SAS were used to investigate the baseline characteristics associated with mortality during the first 60 months of follow-up (corresponding to the observed duration of follow-up for >95% of participants). Candidate predictors included age (in years), gender (male vs. female), residency (rural vs. urban), active tuberculosis, WHO stages of the disease (III-IV vs. I-II), weight (in kg), platelet count (per 1000), CD4 count (per 10/mm<sup>3</sup>), haemoglobin level (in g/dl) and ART regimen (AZT vs. no AZT). Candidate predictors were tested one at a time in a basic model that included gender and age as covariates. Then significant predictors (based on a p-value <0.10) were entered together in a multivariable model, and significant ones kept in the final model alongside age and gender. The reference category (or direction of continuous predictors) was always rearranged as appropriate to identify levels associated with increased mortality risk. A p-value < 0.05 was used to characterise statistically significant results.

## RESULTS

### Data available

In 2007 and 2008, a total of 1444 PLHIV [including 827 women (57.3%)] were started on ART at the YJH's ATC. Medical files were available for all of them. However, data were missing on some characteristics for few participants. Analyses for those characteristics are restricted to participants with valid data, and their number indicated where relevant. Furthermore, a total of 470 participants had missing data for at least one of the candidate predictors, and were therefore excluded from regression analysis. Compared with excluded participants, the 974 included in regression analysis had similar age (38.3 vs. 38.8 years, p=0.44), mean CD4 count (102 vs. 111/mm<sup>3</sup>, p=0.06). Furthermore, they had similar proportion of men (42.5% vs. 43.2%, p=0.82), similar distribution across WHO stages of disease severity (p=0.75), a borderline higher prevalence of active tuberculosis (31.1% vs. 26.6%, p=0.04), a borderline lower baseline weight (57.6 vs. 59.1

kg,  $p=0.04$ ) and lower platelet ( $262000$  vs.  $243000/\text{mm}^3$ ,  $p=0.03$ ), and a significantly lower haemoglobin level ( $9.9$  vs.  $10.4$  g/dl,  $p<0.0001$ ).

### Baseline characteristics of the study population

The baseline demographic, clinical and biological characteristics of participants are summarised in Table 1. The median age (25<sup>th</sup>-75<sup>th</sup> percentiles) was 38 (31 - 45) years overall, 40 (34 - 47) years in men and 35 (30 - 43) years in women,  $p<0.0001$ . In all 85.6% of participants were urban dwellers and about the same proportion were started on ART at WHO stage III-IV of disease severity, similarly among men and women (both  $p\geq 0.82$ , Table 1). The main opportunistic infection was tuberculosis, which was found in 428 (29.6%) patients, and was more frequent in men than in women (34.7% vs. 27.9%,  $p=0.0003$ ). The median CD4 count (25<sup>th</sup> - 75<sup>th</sup> percentiles) was 99 (36 - 161) per  $\text{mm}^3$  overall, 89 (33 - 155) in men and 105 (39 - 166) in women ( $p=0.02$ ).

### Follow-up and outcome

The median duration of follow-up (25<sup>th</sup> - 75<sup>th</sup> percentiles) was 14.4 (1.0 - 46.2) months overall, 9.1 (0 - 44.1) months in men and 20.3 (1.3 - 47.3) months in women ( $p<0.0001$ ). At the final evaluation, 235 (cumulative incidence rate 16.3 %) were deceased, 590 (40.8%) were lost to follow-up, 173 (12 %) had been transferred to another centre, while 446 patients (30.9%) were still under active follow-up in the centre. The median duration of follow-up (25<sup>th</sup> - 75<sup>th</sup> percentiles) for non-fatal outcomes was 4.5 (0 - 23.8) months for defaulters, 8.2 (2.5 - 20.3) months for transfer out, and 50.5 (45.9 - 56.7) months for active follow-up cases.

Of the 235 deaths recorded, 208 (88.5 %) deaths occurred early (within the first year of ART) while 27 (11.5%) were late-occurring deaths. Overall, 54.9% of all deaths occurred within one month of starting antiretroviral therapy, 19.6% between 1 and 3 months, 8.5% between 3 and 6 months and 5.5% between 6 and 12 months. The cumulative survival probability from Kaplan-Meier estimators was 84.7% (95% confidence interval: 82.7-86.7) at 6 months, 83.3% (81.3-85.4) at 12 months, 81.7% (79.5-83.9) at 24 months, and 79.3% (76.0-82.5) at 60 months of follow-up. The survival probability from Kaplan-Meier estimators and Weibull plot of the cumulative distribution function for all-cause mortality are depicted in Figure 1. The cumulative mortality rate was 16.8% (79/470) among participants with missing data on at least one of the candidate predictor variables, and 16.6% (162/974) among those with valid data,  $p=0.93$ .

## Determinants of all-cause mortality

The estimated cumulative distribution function for all-cause mortality by major subgroups is depicted in figure 2. In sex and age adjusted analyses, male sex, active tuberculosis, WHO stage III-IV of the disease, lower weight, lower CD4 count and lower baseline haemoglobin level were potential determinants of all-cause mortality (Table 2). In multivariable Weibull regression models with simultaneous adjustment for age, sex, and all the potential factors, all determinants remained significantly associated with all-cause mortality during follow-up (Table 2). Effect estimates (hazard ratio) and 95% confidence intervals were 2.15 (1.34-3.45) for male sex, 2.35 (1.40-3.92) for active tuberculosis, 3.63 (1.29-10.24) for WHO stage III-IV of the disease severity, 1.03 (1.01-1.05) per kilogram lower weight, 1.04 (1.01-1.07) per 10 lower CD4/mm<sup>3</sup> and 1.12 (1.00-1.26) for each g/dl lower baseline haemoglobin (Table 2).

## DISCUSSION

This study conducted in a referral centre for tuberculosis and HIV care in Cameroon revealed a high mortality rate among patients started on ART, with the large majority of deaths occurring during the first year of starting the treatment. Male gender, active tuberculosis, advanced stage of the disease, low CD4 count, low weight and low haemoglobin levels at baseline were significant predictors of all-cause mortality during follow-up. Accounting for these factors may help in refining the prescription of ART and improving the outcome of care among patients with HIV infection.

The survival probability at one year of follow-up after starting ART was found to be much lower (83.3% vs. 77%) in a previous study among 1187 PLHIV infection in a rural setting in the Northern part of Cameroon.[10] This study however, was conducted prior 2007, the year of the implementation of the program of free access to ART in the country, which suggests that this strategy has likely improved survival among PLHIV in the country. It can also be speculated that the difference between this previous study and our finding just reflects differences in the level of care provided in a referral centre like ours, and a rural centre where care can be very basic. The similarities in the baseline profile of participants across the two studies are in support of this hypothesis. For instance, in both studies over 85% of participants were started on ART while at the WHO stage III or IV of the disease severity, while pre-ARV CD4 count was lower than 50/mm<sup>3</sup> in over a quarter of participants at baseline. However, the one-year survival rate in our study is within the range of those reported in previous studies. In recent meta-analysis of those studies, the pooled estimated one-year probability of death from studies conducted in Africa was 17% (95% confidence interval: 11-24 %).[6,15]

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Predictors of mortality identified in our study were essentially those described in existing reports.[6,15] The adverse profile of modifiable risk factors clearly suggests that patients with HIV in our centre are started on ART at an advanced stage of the disease. This likely reflects the fact that in this setting, with the exception of screening in particular circumstances such as during pregnancy or pre-surgical interventions, PLHIV mostly get screened only when they seek medical care with clinical symptoms. This is a common attitude across Africa, and may explain the higher early mortality rate on ART in Africa, compared with other parts of the world.[6] In addition to the advanced clinical stage of the disease on the WHO scale at presentation, body weight, CD4 count and haemoglobin levels were low at baseline, and all significantly associated with high risk of mortality during follow-up as previously reported.[5,8] It is of note that at the time this study was conducted, most patients were started on ART at CD4 count below 200/mm<sup>3</sup>. Recent WHO recommendations favour ART initiation at CD4 count below 350/mm<sup>3</sup>. Their uptake may potentially reduce early mortality rate, as a result of many patients starting treatment at favourable CD4 levels. The prevalence of active tuberculosis in our study was possibly inflated by the nature of the study setting as a referral centre for tuberculosis treatment, where most patients with both HIV and tuberculosis are more likely to be referred for care. The resulting subsample of participants with both conditions has possibly increased our statistical power for uncovering baseline active tuberculosis as a risk factor for mortality among PLHIV started on antiretroviral therapy. Such an association has been inconsistently reported in previous studies.[6,10,16]

Free access to ART was introduced in Cameroon in May 2007.[17] We have recently reported rates of non-adherence to ART to be as high as 34% among patients with HIV receiving chronic care at the YJH in the era of free access to ART.[12] In the absence of any assessment of the adherence to ART in the current study, it is difficult to speculate on a contribution, if any, of non-adherence to ART to the observed high mortality in our study. However, such an effect is likely marginal in this setting where mortality mostly occurs early when patients have not been exposed to ART enough to derive therapeutic benefits. Furthermore, existing instruments for measuring adherence to ART are likely unsuitable for investigating premature mortality risk. The main non-modifiable risk factor of mortality in our study was male sex. This was not fully explained by sex differences in the level of other risk factors. Indeed, with the exception of baseline CD4 count which was lower in men, other factors were equally distributed among men or women or rather showed more favourable levels in men. Other studies have shown that adherence to prescribed ART was better in women than in men, [18] which can explain differing rates of mortality between men and women started on ART.

Our study has some limitations, including the missing data, which are expected for a study conducted on data collected from patients files, and when dealing with large numbers of

1 participants. Drop-out through losses to follow-up potentially included deceased patients, and may  
2 be in high proportion based on some studies.[19] Therefore, the reported mortality rate in our study  
3 is likely underestimated. But such a bias is unlikely to affect the associations of major risk factors  
4 with the mortality outcome as shown elsewhere.[10] In the absence of any evaluation of the  
5 adherence to ART, particularly among early mortality survivors, we were unable to investigate a  
6 potential effect of non-adherence to ART on mortality risk in the current study. Our study also has  
7 major strengths including the large sample size, which increased our statistical power to reliably  
8 characterise the predictors of mortality. The mortality rate following ART initiation as found in our  
9 study and other published studies is not constant over time. It is very high in the early months of  
10 starting the treatment, and subsequently drops and stabilises at a much lower rate. Many previous  
11 studies have been based on statistical methods that assume constant mortality rates over time such  
12 as the person-year methods, and have likely generated less reliable estimates of the association of  
13 predictors with mortality risk. We have attempted to address this limitation by applying the  
14 accelerated failure time models in our study. Unlike Cox models for instance, regression parameters  
15 estimates from accelerated failure time models are robust to the omitted covariates, and are  
16 unaffected by the choice of probability distribution.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

29 In conclusion, mortality rate among patients with HIV-1 infection started on antiretroviral  
30 therapy in this setting remains unacceptably high. Deaths occur mostly within the first year of  
31 starting treatment and essentially among patients with clinical and biological profiles compatible  
32 with an advanced stage of the disease at the time when antiretroviral treatment is started. Strategies  
33 for early detection of patient with HIV at the clinically asymptomatic stages followed by early  
34 initiation of antiretroviral therapy, need to be developed and tested in this setting. Recent updates of  
35 the country's guidelines for HIV treatment, recommending prescription of antiretroviral therapy at  
36 CD4 count lower than  $350/\text{mm}^3$  have a potential for significantly reducing premature mortality  
37 among people with HIV in this setting.  
38  
39  
40  
41  
42  
43  
44

45 **Funding:** No funding was received for this study.

46  
47 **Competing interests:** None for all authors.

48  
49  
50 **Ethics approval:** Ethics approval was obtained from the Institutional Review Board of the  
51 Yaounde Jamot Hospital.

52  
53  
54 **Contributors:** VPM, collected data, co-analysed the data and drafted the manuscript. EWPY  
55 conceived the study, supervised data collection, co-analysed the data and drafted the manuscript.  
56 APK contributed to study design, data analysis, drafting and critical revision of the manuscript. CK  
57  
58  
59  
60



1 supervised data collection and critically revised the manuscript. All authors approved the final  
2 version of the manuscript.  
3  
4

5 **Data sharing:** No additional data available.  
6  
7  
8  
9

## 10 REFERENCES

- 11 1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Report on the global AIDS  
12 epidemic. 2012  
13 [http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr201](http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_UNAIDS_Global_Report_2012_en.pdf)  
14 [2/20121120\\_UNAIDS\\_Global\\_Report\\_2012\\_en.pdf](http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_UNAIDS_Global_Report_2012_en.pdf) (Accessed 6 May 2013)  
15  
16
- 17 2. Braitstein P, Brinkhof MW, Dabis F *et al*. Mortality of HIV-1-infected patients in the first  
18 year of antiretroviral therapy: comparison between low-income and high-income countries.  
19 *Lancet* 2006;**367**:817-824.  
20
- 21 3. Palella FJ, Baker RK, Moorman AC *et al*. Mortality in the highly active antiretroviral  
22 therapy era: changing causes of death and disease in the HIV outpatient study. *J Acquir*  
23 *Immune Defic Syndr* 2006;**43**:27-34.  
24
- 25 4. Marazzi MC, Liotta G, Germano P *et al*. Excessive early mortality in the first year of  
26 treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited  
27 settings. *AIDS Res Hum Retroviruses* 2008;**24**:555-560.  
28
- 29 5. Kouanda S, Meda IB, Nikiema L *et al*. Determinants and causes of mortality in HIV-  
30 infected patients receiving antiretroviral therapy in Burkina Faso: a five-year retrospective  
31 cohort study. *AIDS Care* 2012;**24**:478-90.  
32
- 33 6. Gupta A, Nadkarni G, Yang WT *et al*. Early mortality in adults initiating antiretroviral  
34 therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-  
35 analysis. *PLoS One* 2011;**6**:e28691.  
36
- 37 7. Fregonese F, Collins IJ, Jourdain G *et al*. Predictors of 5-years mortality in HIV-infected  
38 adults starting highly active antiretroviral therapy (HAART) in Thailand. *J Acquir Immune*  
39 *Defic Syndr* 2012;**60**:91-8.  
40
- 41 8. Laurent C, Meilo H, Guiard-Schmid JB *et al*. Antiretroviral therapy in public and private  
42 routine health care clinics in Cameroon: lessons from the Douala antiretroviral (DARVIR)  
43 initiative. *Clin Infect Dis* 2005;**41**:108-111.  
44
- 45 9. Ministère de la Santé Publique. Rapport national de suivi de la déclaration politique sur le  
46 VIH/SIDA Cameroun 2012.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



10. Sieleunou I, Souleymanou M, Schonenberger AM et al. Determinants of survival in AIDS patients on antiretroviral therapy in a rural centre in the Far-North Province, Cameroon. *Trop Med Int Health* 2009;**14**:36-43.
11. Pefura Yone EW, Betyoumin AF, Kengne AP et al. First-line antiretroviral therapy and dyslipidemia in people living with HIV-1 in Cameroon: a cross-sectional study. *AIDS Res Ther* 2011;**8**:33.
12. Pefura Yone EW, Soh E, Kengne AP et al. Non-adherence to antiretroviral therapy in Yaounde: Prevalence, determinants and the concordance of two screening criteria. *Journal of Infection and Public Health* 2013. doi:10.1016/j.jiph.2013.02.003.
13. Ministère de la Santé Publique du Cameroun. Directives nationales de prise en charge par les antirétroviraux des personnes (adultes et adolescents) infectés par le VIH. Yaoundé 2007.
14. Wools-Kaloustian K, Kimaiyo S, Diero L et al. Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. *Aids* 2006;**20**:41-48.
15. Biadgilign S, Reda AA, Digaffe T. Predictors of mortality among HIV infected patients taking antiretroviral treatment in Ethiopia: a retrospective cohort study. *AIDS Res Ther* 2012;**9**:15.
16. Amuron B, Levin J, Birunghi J et al. Mortality in an antiretroviral therapy programme in Jinja, south-east Uganda: a prospective cohort study. *AIDS Res Ther* 2011;**8**:39.
17. Ministry of Public Health, Republic of Cameroon. National AIDS Control Committee: Towards universal access to care and treatment for adults and children living with HIV/AIDS in Cameroon. Progress Report N° 4. 2006.
18. MacPherson P, Moshabela M, Martinson N et al. Mortality and loss to follow-up among HAART initiators in rural South Africa. *Trans R Soc Trop Med Hyg* 2009, **103**:588-593.
19. Yu JK, Chen SC, Wang KY et al. True outcomes for patients on antiretroviral therapy who are "lost to follow-up" in Malawi. *Bull World Health Organ* 2007;**85**:550-554.

Table 1 Demographic, clinical and biological profile of HIV patients started on antiretroviral therapy at the Yaounde Jamot Hospital in 2007 and 2008

Characteristics*	Overall	Men	Women	p-value
n	1444	617	827	
Median age, years (25 <sup>th</sup> -75 <sup>th</sup> percentile)	38 (31-45)	40 (34-47)	35 (30-43)	<0.0001
Residence, n (%)				0.98
Urban	1236 (85.6)	528 (85.6)	708 (85.6)	
Rural	208 (14.4)	89 (14.4)	119 (14.4)	
Tuberculosis, n (%)	428 (29.6)	214 (34.7)	214 (27.9)	0.0003
Weight, Kg				<0.0001
< 50, n (%)	308/1322 (23.3)	69/570 (12.1)	239/752 (31.8)	
50-60, n (%)	535/1322 (40.5)	204/570 (35.8)	331/752 (44.0)	
>60, n (%)	479/1322 (36.2)	297/570 (52.1)	182/752 (24.2)	
Median (25 <sup>th</sup> -75 <sup>th</sup> percentile)	57 (50 - 65)	61 (54-68)	54 (47.5-60)	<0.0001
WHO stage, n (%)				0.82
I and II	186/1295 (14.4)	78/553 (14.1)	108/742 (14.6)	
III and IV	1109/1295 (85.6)	475/553 (85.9)	634/742 (85.4)	
Platelets, X1000/mm <sup>3</sup>	244 (180– 320)	229 (173-309)	259 (190-330)	0.0005
Total lymphocytes, X10/mm <sup>3</sup>	130 (90–190)	130 (90-201)	130 (90-190)	0.88
CD4, /mm <sup>3</sup>				0.21
< 50, n (%)	468 (32.4)	216 (30.5)	256 (30.5)	
50-99, n (%)	257 (17.8)	111 (18.0)	142 (17.6)	
100-200, n (%)	562 (38.9)	231 (37.4)	331 (40.0)	
>200, n (%)	157 (10.9)	59 (9.6)	98 (11.8)	
Median (25 <sup>th</sup> -75 <sup>th</sup> percentile)	99 (36.2-161)	89 (33-155)	105 (39-166)	0.02
Haemoglobin, g/dl,				<0.0001
< 8, n (%)	235/1388 (16.9)	67/594 (11.3)	168/794 (21.2)	
8-10, n (%)	506/1388 (36.5)	178/594 (30.0)	328/794 (41.3)	
>10, n (%)	647/1388 (46.6)	349 (58.7)	298 (37.5)	
Median, (25 <sup>th</sup> -75 <sup>th</sup> percentile)	9.9 (8.5-11.2)	10.5 (9-12)	9.5 (8.1-10.7)	<0.0001

NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; WHO, World Health Organisation

\* For all characteristics with missing values, estimates are based of the subset of participants with valid data for each relevant characteristic, and new denominators always provided.

Table 2 Determinants of all-cause mortality among HIV-positive patients started on antiretroviral therapy (n = 1444)

Variable	Age and sex adjusted		Multivariable adjusted	
	Hazard Ratio (95% CI)	p	Hazard Ratio (95% CI)	p
Age, per year	1.01 (0.98-1.03)	0.56	1.01 (0.99-1.03)	0.37
Male sex	1.44 (0.94-2.11)	0.10	2.15 (1.34-3.45)	0.002
Rural residency	1.14 (0.62-2.09)	0.68	-	
Active tuberculosis	1.59 (0.97-2.61)	0.07	2.35 (1.40-3.92)	0.002
WHO stage III-IV	4.57 (1.68-12.47)	0.004	3.63 (1.29-10.24)	0.02
Weight, per kg lower	1.04 (1.02-1.06)	0.0002	1.03 (1.01-1.05)	0.01
Platelet count, per 1000 lower	1.01 (0.99-1.03)	0.53	-	
CD4 count, per 10/mm <sup>3</sup> lower	1.06 (1.02-1.09)	0.003	1.04 (1.01-1.07)	0.02
Haemoglobin, per g/dl lower	1.14 (1.03-1.26)	0.02	1.12 (1.00-1.26)	0.05
AZT based regimens	0.91 (0.51-1.62)	0.76	-	

AZT, zidovudine; CI, confidence interval; WHO, World Health Organisation

Mortality and its determinants among HIV-1 patients infected patients with HIV-1 on antiretroviral therapy in a referral centre in Yaounde, Cameroon: a retrospective cohort study

Short title: Determinants of death among patients with HIV infection

Virginie POKA-MAYAP (1), Eric Walter PEFURA-YONE (1, 2), André Pascal KENGNE (3), Christopher KUABAN (1, 4)

- 1) Pneumology Service, Yaounde Jamot Hospital, Cameroon
2) Department of Internal Medicine and Subspecialties, Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Cameroon
3) South African Medical Research Council & University of Cape Town, Cape Town, South Africa
4) Faculty of Health Sciences, University of Bamenda, Cameroon

Correspondence to:

Dr Virginie Poka-Mayap,
Yaounde Jamot Hospital,
PO Box 4021-Yaounde, Cameroon
Tel: (237)99253759,
Email: pokavirginie@yahoo.fr

Formatted: English (U.K.)

Formatted: Font color: Auto

Tables: 2

Figures: 0

Online only material: 0

Word count: abstract-267270; Main text (excluding tables, figures, abstract & references)-26642933

References: 1819

Formatted: No underline, Font color: Auto, English (U.K.)

Formatted: English (U.K.)

Formatted: No underline, Font color: Auto, English (U.K.)

Formatted: No underline, Font color: Auto, English (U.K.)

Formatted: English (U.K.)

Formatted: No underline, Font color: Auto, English (U.K.)

Formatted: English (U.K.)

## ABSTRACT

**Objectives:** Mortality has ~~decreased~~declined in people with human immunodeficiency virus (HIV) infection, subsequent to the improved access to antiretroviral therapy (ART). We assessed the incidence and determinants of ~~fatal-outcomes~~mortality among patients with HIV-1 infection, started on ART in a referral treatment centre for HIV infection in Yaounde, Cameroon.

**Design:** Cohort study with baseline assessment between 2007 and 2008, and follow-up during five years until June 2012.

**Setting:** The ~~approved-centre-for~~accredited HIV treatment centre of the Yaounde Jamot Hospital, in capital city of Cameroon.

**Participants:** ~~Patients~~People living with HIV infection who ~~were~~ started ART between 2007 and 2008 at the study centre.

**Outcome measures:** All-cause mortality over time, ~~with the~~ accelerated failure time models ~~were~~ used to relate baseline characteristics ~~with~~to mortality occurrence during follow-up.

**Results:** Of the 1444 patients included, 827 (53.7%) were men, and the median age (25<sup>th</sup>-75<sup>th</sup> percentiles) was 38 (31-45) years. The median duration of follow-up was 14.1 (1.1-46.4) months, during which 235 deaths were recorded (cumulative incidence rate: 16.3%), including 208 (88.5%) during the first year of follow-up. Baseline predictors of mortality were male gender [adjusted hazard ratio 2.15 (95%~~CI~~confidence interval: 1.34-3.45)], active tuberculosis [2.35 (1.40-3.92)], WHO stages III-IV of the disease [3.63 (1.29-10.24)], low weight [1.03 (1.01-1.05) per kilogramme], low CD4 count [1.04 (1.01-1.07) per 10/mm<sup>3</sup> lower CD4] and low haemoglobin levels [1.12 (1.00-1.26) per g/dl lower].

**Conclusions:** ~~Death~~Mortality rate among patients with HIV is very high within the first year of starting ART in this centre. Early start of the treatment, at a less advanced stage of the disease, and ~~much~~-favourable levels of CD4 and other predictors ~~may improve the outcomes of patients~~could reduce early mortality, but would have to be tested.

*Word count – 267270*

*Key words:* HIV infection, ~~death~~mortality, determinants, cohort, Cameroon, antiretroviral therapy

Formatted: No underline, Font color: Dark Red

## ARTICLE SUMMARY

### Article focus

- To investigate mortality occurrence and determinants among patients with HIV-1 infection, started on antiretroviral therapy in a major reference treatment centre

### Key messages

- ~~Death~~Mortality rate among patients with HIV is very high, particularly within the first year of starting ARTantiretroviral therapy in this centre
- Male gender, active tuberculosis, advanced stage of the disease, low CD4 count, low weight and low haemoglobin levels at baseline were significant predictors of all-cause mortality during the follow-up

### Strengths and limitations

- Strengths of the study include the large sample size and the use of robust methods to relate baseline predictors to the ~~outcome~~mortality occurrence during follow-up.
- The study was based on data collected from patient files and clinical registers, and as expected there were missing data, particularly on the true outcome of patients who were lost-to-follow-up.

Formatted: No underline, Font color: Dark Red

## INTRODUCTION

Human immunodeficiency virus (HIV) infection is a major global health problem. Sub-Saharan Africa (SSA), with about 68% of the global population with HIV, is the most affected region in the world.<sup>[1], [1]</sup> HIV related mortality appears to be higher in developing than in developed countries.<sup>[2], [2]</sup> Hopefully, mortality rates are ~~on the decline~~declining with the improved access to antiretroviral therapy,<sup>[3] (ART), [3]</sup> while explaining factors ~~of~~for the residual deaths ~~seems seem~~ to vary significantly across populations. Studies in SSA have found that mortality rate is particularly high during the first year of starting ~~antiretroviral therapy,~~ <sup>[4] ART, [4]</sup> with male sex, cachexia, advanced stage of the disease, low CD4 count, anaemia, high viral load at baseline, and poor adherence to treatments being the main determinants of ~~death.~~ <sup>[5-8] mortality. [5-8]</sup>

~~In Cameroon, about 105,000 people with HIV infection were on antiretroviral therapy by the end of the year 2011. [9] A study conducted in 2006 in a rural unit for HIV treatment in the northern part of the country, found a mortality rate of 20.2/100 person years among HIV patients receiving antiretroviral therapy. [10] This figure however, has not been updated since the introduction of free access to antiretroviral therapy in the country. Thus, the aim of this study was to determine the mortality rate and its determinants among patients with HIV-1 infection, started on antiretroviral therapy in a reference treatment centre in Cameroon.~~

~~In Cameroon, about 105,000 people living with HIV (PLHIV) infection were on ART by the end of the year 2011. [9] A study conducted in 2006 in a rural unit for HIV treatment in the northern part of the country, found a mortality rate of 20.2/100 person-years among HIV patients receiving ART. [10] This figure however, has not been updated since 2007, the year of introduction of free access to ART in the country. Thus, the aim of this study was to determine the mortality rate and determinants among patients with HIV-1 infection, started on ART in a reference treatment centre in Cameroon.~~

## PARTICIPANTS AND METHODS

### Study setting ~~and participants~~

Formatted: Font color: Dark Red

The study was conducted in the ~~approved~~accredited HIV treatment centre (ATC) of the Yaounde Jamot Hospital (YJH) in the ~~Capital~~capital city of Cameroon. The study setting has been described in ~~detail~~details previously ~~elsewhere.~~ <sup>[11, 12], [11, 12]</sup> In brief, YJH is the referral centre for tuberculosis and chest diseases for the Capital city (Yaounde) and surrounding areas. It has an ~~approved treatment centre (ACT)~~ATC that provides care to ~~people with HIV infection.~~ <sup>PLHIV.</sup> As



of June 2011, ~~the active file total of HIV-infected persons 2,250 PLHIV were~~ followed in the centre ~~was 2250 patients. Patients received at ATC between January 2007 and December 2008, aged 18 years and above, and who were started on ART, were included in the study.~~

Formatted: No underline, Font color: Dark

Formatted: Font color: Dark Red, English (U.S.)

### *Care of patients with HIV infection*

~~During the study period, patients with HIV infection were started on antiretroviral therapy in the presence of a CD4 count below 200/mm<sup>3</sup> or superimposed condition other than tuberculosis, characteristic of WHO stage IV of the disease severity, [13] Patients fulfilling these criteria were referred to the ACF~~ During the study period, PLHIV were started on ART in the presence of a CD4 count below 200/mm<sup>3</sup> or superimposed conditions other than tuberculosis, compatible with the WHO stage IV of the disease severity. [13] Patients fulfilling these criteria were referred to the ATC for treatment inception and follow-up. A medical file was created under the supervision of the attending physician and included socio-demographic, clinical and biological data of the patient. Files of eligible patients were presented at weekly meetings during which the appropriate treatment regimen ~~for each patient~~ was decided. First line treatment regimens included two nucleoside reverse transcriptase inhibitors (zidovudine, ~~didanosine~~, lamivudine, tenofovir) and one non-nucleoside reverse transcriptase inhibitor (nevirapine or efavirenz). Second line regimens comprised two nucleoside reverse transcriptase inhibitors (zidovudine, didanosine, lamivudine, tenofovir) and a protease inhibitor (indinavir, lopinavir/ritonavir). These regimens were all dispensed to patients free of charge and they were all started on prophylactic treatment with cotrimoxazole. All patients had ~~an~~ interaction session with trained psychosocial advisors, to improve adherence to prescribed therapies.

Patients registered at the YJH's ~~ACF~~ ATC are seen on a monthly basis for prescription renewal. For those on a regimen comprising zidovudine (AZT) and/or nevirapine (NVP), haemoglobin (AZT) and/or liver transaminases (NVP) levels are monitored at two weeks from starting treatment. A biological profile is requested every six months, comprising a CD4 count, full blood count, liver transaminases and creatinin (only for patients receiving tenofovir), and results are recorded in the clinical ~~file~~ files.

### **Outcome**

During the study period, patients who failed to report for consultation for three consecutive months were traced by community liaison agents using the contact details on the file. All-cause mortality was considered for all deceased patients at any time after starting ~~antiretroviral therapy-ART~~. The time-to-death (in months) was the interval from the start of the ~~antiretroviral~~

therapy~~ART~~ to date of death (or date of the last recorded visit when the date of death was unknown). Loss-to-follow-up (defaulter) was ~~considered for patients defined as a patient~~ who failed to return for consultation for three consecutive months and was unsuccessfully traced by liaison agents. ~~[14], [14]~~ Transfer was considered for patients who at any time were definitively transferred to receive care in another centre. The follow-up for all patients was until June 2012, death, transfer and loss to follow-up, whichever came first.

### Data collection

For the purpose of this study, patients with HIV started on ~~antiretroviral therapy between January 2007 and December 2008~~ ~~ART during the study period~~ were identified via antiretroviral treatment registries. All patients with HIV-1 infection, aged 18 years and above, started on ~~antiretroviral~~ ~~ART~~ during this period were included in the study, and followed until June 2012 ~~(5.5 years)~~. The study was approved by the regulatory board of YJH.

The following data were ~~then~~ retrieved in the medical files of eligible patients: sex, baseline age (in years), residence (urban vs. rural), weight in Kg, presence of opportunistic infection, CD4 count ~~(in cells/mm<sup>3</sup>)~~, haemoglobin levels in g/dl, total lymphocytes and platelet counts, antiretroviral regimens; ~~the outcome: (death, loss-to-follow-up, transfer out, still alive and followed-up)~~, and estimated time to the outcome occurrence in months. The duration of follow-up for patients still actively followed-up was censored in June 2012.

### Statistical analysis

Data analysis used SPSS v17.0 (SPSS Inc., Chicago, USA) and SAS/STAT® v 9.1 for Windows (SAS Institute Inc., Cary, NC, USA). Results are presented as count and percentages, mean and standard deviation or median and 25<sup>th</sup>-75<sup>th</sup> percentiles. The chi square test, Student's t-test and ~~their non-parametric~~ equivalents were used to compare baseline characteristics. The Kaplan-Meier estimator and accelerated failure time models, implemented with the use of LIFETEST and LIFEREG procedures of SAS were used to investigate the baseline characteristics associated with mortality during the first 60 months of follow-up (corresponding to the observed duration of follow-up for ~~>95% of participants~~ 95% of participants). Candidate predictors included age (in years), gender (male vs. female), residency (rural vs. urban), active tuberculosis, WHO stages of the disease (III-IV vs. I-II), weight (in kg), platelet count (per 1000), CD4 count (per 10/mm<sup>3</sup>), haemoglobin level (in g/dl) and ART regimen (AZT vs. no AZT). Candidate predictors were tested one at a time in a basic model that included gender and age as covariates. Then significant predictors (based on a p-value <0.10) were entered together in a multivariable

**Formatted:** No underline, Font color: Dark Red, English (South Africa)

**Formatted:** Font color: Dark Red, English (U.S.)

1  
2  
3  
4  
5  
6 model, and significant ones kept in the final model alongside age and gender. The reference  
7 category (or direction of continuous predictors) was always rearranged as appropriate to identify  
8 levels associated with increased mortality risk. A p-value < 0.05 was used to characterise  
9 statistically significant results.  
10  
11

## 12 13 14 **RESULTS**

### 15 **Baseline characteristics of the study population**

#### 16 **Data available**

17  
18  
19  
20 In 2007 and 2008, a total of 1444 ~~patients with HIV infection~~ PLHIV [including 827 women  
21 (57.3%)] were started on ~~antiretroviral treatment~~ ART at the YJH's ~~ACT/ATC~~. Medical files were  
22 available for all of them. However, data were missing on some characteristics for few participants.  
23 Analyses for those characteristics are restricted to participants with valid data, and their number  
24 indicated where relevant. Furthermore, a total of 470 participants had missing data for at least one  
25 of the candidate predictors, and were therefore excluded from regression analysis. Compared with  
26 excluded participants, the 974 included in regression analysis had similar age (38.3 vs. 38.8 years,  
27 p=0.44), mean CD4 count (102 vs. 111/mm<sup>3</sup>, p=0.06). Furthermore, they had similar proportion of  
28 men (42.5% vs. 43.2%, p=0.82), similar distribution across WHO stages of disease severity  
29 (p=0.75), a borderline higher prevalence of active tuberculosis (31.1% vs. 26.6%, p=0.04), a  
30 borderline lower baseline weight (57.6 vs. 59.1 kg, p=0.04) and lower platelet (262000 vs.  
31 243000/mm<sup>3</sup>, p=0.03), and a significantly lower haemoglobin level (9.9 vs. 10.4 g/dl, p<0.0001).  
32  
33  
34  
35  
36  
37

### 38 **Baseline characteristics of the study population**

39  
40 The baseline demographic, clinical and biological characteristics of participants are  
41 summarised in Table 1. The median age (25<sup>th</sup>-75<sup>th</sup> percentiles) was 38 (31 - 45) years overall, 40  
42 (34 - 47) years in men and 35 (30 - 43) years in women,  $p \ll 0.0001$ . In all 85.6% of participants  
43 were urban dwellers and about the same proportion were started on ~~antiretroviral therapy~~ ART at  
44 WHO stage III-IV of disease severity, similarly among men and women (both  $p \gg 0.82$ , Table 1).  
45 The main opportunistic infection was tuberculosis, which was found in 428 (29.6%) patients, and  
46 was more frequent in men than in women (34.7% vs. 27.9%,  $p = 0.0003$ ). The median CD4 count  
47 (25<sup>th</sup> - 75<sup>th</sup> percentiles) was 99 (36 - 161) per mm<sup>3</sup> overall, 89 (33 - 155) in men and 105 (39 - 166)  
48 in women ( $p = 0.01802$ ).  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Follow-up and outcome

The median duration of follow-up (25<sup>th</sup> - 75<sup>th</sup> percentiles) was 14.4 (1.0 - 46.2) months overall, 9.1 (0 - 44.1) months in men and 20.3 (1.3 - 47.3) months in women ( $p \leq 0.0001$ ). At the final evaluation, 235 (cumulative incidence rate 16.3%) were deceased, 590 (40.8%) were lost to follow-up, 173 (12%) had been transferred to another centre, while 446 patients (30.9%) were still under active follow-up in the centre. The median duration of follow-up (25<sup>th</sup> - 75<sup>th</sup> percentiles) for non-fatal outcomes was 4.5 (0 - 23.8) months for defaulters, 8.2 (2.5 - 20.3) months for transfer out, and 50.5 (45.9 - 56.7) months for active follow-up cases.

Of the 235 deaths recorded, 208 (88.5%) deaths occurred early (within the first year of ART) while 27 (11.5%) were late-occurring deaths. Overall, 54.9% of all deaths occurred within one month of starting antiretroviral therapy, 19.6% between 1 and 3 months, 8.5% between 3 and 6 months and 5.5% between 6 and 12 months. The cumulative survival probability from Kaplan-Meier estimators was 84.7% (95% confidence interval: 82.7—86.7) at 6 months, 83.3% (81.3—85.4) at 12 months, 81.7% (79.5—83.9) at 24 months, and 79.3% (76.0—82.5) at 60 months of follow-up. The survival probability from Kaplan-Meier estimators and Weibull plot of the cumulative distribution function for all-cause mortality are depicted in Figure 1. The cumulative mortality rate was 16.8% (79/470) among participants with missing data on at least one of the candidate predictor variables, and 16.6% (162/974) among those with valid data,  $p=0.93$ .

## Determinants of all-cause mortality

The estimated cumulative distribution function for all-cause mortality by major subgroups is depicted in figure 2. In sex and age adjusted analyses, male sex, active tuberculosis, WHO stage III-IV of the disease, lower weight, lower CD4 count and lower baseline haemoglobin level were potential determinants of all-cause mortality (Table 2). In multivariable Weibull regression models with simultaneous adjustment for age, sex, and all the potential factors, all determinants remained significantly associated with all-cause mortality during follow-up (Table 2). Effect estimates (hazard ratio) and 95% confidence intervals were 2.15 (1.34-3.45) for male sex, 2.35 (1.40-3.92) for active tuberculosis, 3.63 (1.29-10.24) for WHO stage III-IV of the disease severity, 1.03 (1.01-1.05) per kilogram lower weight, 1.04 (1.01-1.07) per 10 lower CD4/mm<sup>3</sup> and 1.12 (1.00-1.26) for each g/dl lower baseline haemoglobin (Table 2).

Formatted: Font: Bold

## DISCUSSION

This study conducted in a referral centre for tuberculosis and HIV care in Cameroon revealed a high mortality rate among patients started on [antiretroviral therapy ART](#), with the large majority of [deathdeaths](#) occurring during the first year of starting the treatment. Male gender, active tuberculosis, advanced stage of the disease, low CD4 count, low weight and low haemoglobin levels at baseline were significant predictors of all-cause mortality during follow-up. Accounting for these factors may help in refining the prescription of [antiretroviral therapy ART](#) and [improveimproving](#) the outcome of care among patients with HIV infection.

The survival probability at one year of follow-up after starting [antiretroviral therapy ART](#) was found to be much lower (83.3% vs. 77%) in a previous study among 1187 [patients with HIVPLHIV](#) infection in a rural setting in the Northern part of Cameroon-[\[10\].\[10\]](#) This study however, was conducted prior ~~to~~ [2007](#), the [year of the](#) implementation of the program of free access to [antiretroviral therapy ART](#) in the country, which suggests that this strategy has likely improved survival among [HIV-patientsPLHIV](#) in the country. It can also be speculated that the difference between this previous study and our [studyfinding](#) just reflects differences in the level of care provided in a referral centre like ours, and a rural centre where care can be very basic. The similarities in the baseline profile of participants across the two studies are in support of this hypothesis. For instance, in both studies over 85% of participants were started on [antiretroviral therapy ART](#) while at the WHO stage III or IV of the disease severity, while pre-ARV CD4 count was lower than 50/mm<sup>3</sup> in over a quarter of participants at baseline. However, the one-year survival rate in our study is within the range of those reported in previous studies. In recent meta-analysis of those studies, the pooled estimated one-year probability of death from studies conducted in Africa was 17% (95% confidence interval: 11-24%), [\[6, 15\] %](#).[\[6.15\]](#)

Predictors of mortality identified in our study were essentially those described in existing reports-[\[6, 15\] \[6.15\]](#). The adverse profile of modifiable risk factors clearly [suggests suggests](#) that patients with HIV in our centre are started on ART at an advanced stage of the disease. This likely reflects the fact that in this setting, with the exception of screening in particular circumstances such as during pregnancy or pre-surgical [intervention, people with HIV infectioninterventions, PLHIV](#) mostly get screened only when they seek medical care with clinical symptoms. This is a common attitude across Africa, [whichand](#) may explain the higher early mortality rate on ART in Africa, compared with other parts of the world-[\[6\].\[6\]](#) In addition to the advanced clinical stage of the disease on the WHO scale at presentation, body weight, CD4 count and haemoglobin levels were low at baseline, and all significantly associated with high risk of mortality during follow-up as

1  
2  
3  
4  
5  
6 previously reported.~~[5-8].~~[5,8] It is of note that at the time this study was conducted, most patients  
7 ~~were started on ART at CD4 count below 200/mm<sup>3</sup>.~~ Recent WHO recommendations favour ART  
8 ~~initiation at CD4 count below 350/mm<sup>3</sup>.~~ Their uptake may potentially reduce early mortality rate, as  
9 ~~a result of many patients starting treatment at favourable CD4 levels.~~ The prevalence of active  
10 tuberculosis in our study was possibly inflated by the nature of the study setting as a referral centre  
11 for tuberculosis treatment, where most patients with both HIV and tuberculosis are ~~more~~ likely to be  
12 referred for care. The resulting subsample of participants with both conditions has possibly  
13 increased our statistical power for uncovering baseline active tuberculosis as a risk factor for ~~fatal~~  
14 ~~outcomes~~mortality among ~~people with HIV~~PLHIV started on antiretroviral therapy. Such an  
15 association has been inconsistently reported in previous studies.~~[6, 10, 16].~~[6,10,16]

20  
21 ~~Free access to ART was introduced in Cameroon in May 2007.~~[17] We have recently reported rates  
22 ~~of non-adherence to ART to be as high as 34% among patients with HIV receiving chronic care at the YJH~~  
23 ~~in the era of free access to ART.~~[12] In the absence of any assessment of the adherence to ART in the  
24 ~~current study, it is difficult to speculate on a contribution, if any, of non-adherence to ART to the observed~~  
25 ~~high mortality in our study. However, such an effect is likely marginal in this setting where mortality mostly~~  
26 ~~occurs early when patients have not been exposed to ART enough to derive therapeutic benefits.~~  
27 ~~Furthermore, existing instruments for measuring adherence to ART are likely unsuitable for investigating~~  
28 ~~premature mortality risk.~~ The main non-modifiable risk factor of mortality in our study was male sex.  
29 This was not fully explained by sex differences in the level of other risk factors. Indeed, with the  
30 exception of baseline CD4 count which was lower in men, other factors were equally distributed  
31 among men or women or rather showed more favourable levels in men. Other studies have shown  
32 that adherence to prescribed ART was better in women than in men, ~~[47].~~[18] which can explain  
33 differing rates of ~~fatal outcomes~~mortality between men and women started on ART.

34  
35  
36  
37  
38  
39 Our study has some limitations, including the missing data, which are expected for a study  
40 conducted ~~based~~ on data collected from patients files, and when dealing with large numbers of  
41 participants. Drop-out through losses to follow-up potentially ~~include~~included deceased patients,  
42 and may be in high proportion based on some studies.~~[48].~~[19] Therefore, the reported mortality  
43 rate in our study is likely underestimated. But such a bias is unlikely to affect the associations of  
44 major risk factors with the mortality outcome as shown elsewhere.~~[40].~~[10] In the absence of any  
45 ~~evaluation of the adherence to ART, particularly among early mortality survivors, we were unable~~  
46 ~~to investigate a potential effect of non-adherence to ART on mortality risk in the current study.~~ Our  
47 study also has major strengths including the large sample size, which increased our statistical power  
48 to reliably characterise the predictors of mortality. The ~~death~~mortality rate following ART initiation  
49 as found in our study and ~~previous~~other published studies is not constant over time. It is very high

Formatted: No underline, Font color: Dark

in the early months of starting the treatment, and subsequently drops and stabilises at a much lower rate. Many previous studies have been based on statistical methods that assume constant

~~death mortality rates~~ over time such as the person-year methods, and have likely generated less reliable estimates ~~of the association of predictors with mortality risk~~. We have attempted to address this limitation by applying the accelerated failure time models in our study. Unlike Cox models for instance, regression parameters estimates from accelerated failure time models are robust to the omitted covariates, and are unaffected by the choice of probability distribution.

In conclusion, mortality rate among patients with HIV-1 infection started on antiretroviral therapy in this setting ~~remain~~remains unacceptably high. Deaths occur mostly within the first year of starting treatment and essentially among patients with clinical and biological profiles compatible with an advanced stage of the disease at the time when antiretroviral treatment is started. Strategies for early detection of patient with HIV ~~and at~~ the clinically asymptomatic stages followed by early initiation of antiretroviral therapy ~~needs, need~~ to be developed and tested in this setting. Recent ~~Cameroonian updates of the country's~~ guidelines ~~of for~~ HIV treatment ~~allowing the, recommending~~ prescription of antiretroviral therapy ~~to patients with at~~ CD4 count lower than 350/mm<sup>3</sup> ~~would probably reduce the~~ have a potential for significantly reducing premature mortality ~~rate among~~ people with HIV in this setting.

**Funding:** ~~This research~~ No funding was received ~~no specific grant from any funding agency in the public, commercial or not-for-profit sectors~~ this study.

**Competing interests:** None for all authors.

**Ethics approval:** Ethics approval was ~~provided by~~obtained from the Institutional Review Board of the Yaounde Jamot Hospital.

**Contributors:** VPM, collected data, co-analysed the data and drafted the manuscript. EWPY conceived the study, supervised data collection, co-analysed the data and drafted the manuscript. APK contributed to study design, data analysis, drafting and critical revision of the manuscript. CK supervised data collection and critically revised the manuscript. All authors approved the final version of the manuscript.

## REFERENCES

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Report on the global AIDS epidemic. 2012

Formatted: No underline, Font color: Dark Red

Formatted: No underline, Font color: Auto, English (U.S.)

Formatted: English (U.S.)

Formatted: No underline, Font color: Auto, English (U.K.)



1  
2  
3  
4  
5  
6 [http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120\\_UNAIDS\\_Global\\_Report\\_2012\\_en.pdf](http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_UNAIDS_Global_Report_2012_en.pdf) (Accessed 6 May 2013)

- 7  
8  
9 2. Braitstein P, Brinkhof MW, Dabis F *et al*. Mortality of HIV-1-infected patients in the first  
10 year of antiretroviral therapy: comparison between low-income and high-income countries.  
11 *Lancet* 2006;**367**:817-824.  
12  
13 3. Palella FJ, Baker RK, Moorman AC *et al*. Mortality in the highly active antiretroviral  
14 therapy era: changing causes of death and disease in the HIV outpatient study. *J Acquir*  
15 *Immune Defic Syndr* 2006;**43**:27-34.  
16  
17 4. Marazzi MC, Liotta G, Germano P *et al*. Excessive early mortality in the first year of  
18 treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited  
19 settings. *AIDS Res Hum Retroviruses* 2008;**24**:555-560.  
20  
21 5. Kouanda S, Meda IB, Nikiema L *et al*. Determinants and causes of mortality in HIV-  
22 infected patients receiving antiretroviral therapy in Burkina Faso: a five-year retrospective  
23 cohort study. *AIDS Care* 2012;**24**:478-90.  
24  
25 6. Gupta A, Nadkarni G, Yang WT *et al*. Early mortality in adults initiating antiretroviral  
26 therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-  
27 analysis. *PLoS One* 2011;**6**:e28691.  
28  
29 7. Fregonese F, Collins IJ, Jourdain G *et al*. Predictors of 5-years mortality in HIV-infected  
30 adults starting highly active antiretroviral therapy (HAART) in Thailand. *J Acquir Immune*  
31 *Defic Syndr* 2012;**60**(+):91-8.  
32  
33 8. Laurent C, Meilo H, Guiard-Schmid JB *et al*. Antiretroviral therapy in public and private  
34 routine health care clinics in Cameroon: lessons from the Douala antiretroviral (DARVIR)  
35 initiative. *Clin Infect Dis* 2005;**41**:108-111.  
36  
37 9. Ministère de la Santé Publique. Rapport national de suivi de la déclaration politique sur le  
38 VIH/SIDA Cameroun 2012.  
39  
40 10. Sieleunou I, Souleymanou M, Schonenberger AM *et al*. Determinants of survival in AIDS  
41 patients on antiretroviral therapy in a rural centre in the Far-North Province, Cameroon.  
42 *Trop Med Int Health* 2009;**14**:36-43.  
43  
44 11. Pefura Yone EW, Betyoumin AF, Kengne AP *et al*. First-line antiretroviral therapy and  
45 dyslipidemia in people living with HIV-1 in Cameroon: a cross-sectional study. *AIDS Res*  
46 *Ther* 2011;**8**:33.  
47  
48 12. Pefura Yone EW, Soh E, Kengne AP *et al*. Non-adherence to antiretroviral therapy  
49 in Yaounde: Prevalence, determinants and the concordance of two screening criteria. *Journal*  
50 *of Infection and Public Health* 2013. doi:10.1016/j.jiph.2013.02.003.  
51  
52  
53  
54

Formatted: No underline, Font color: Auto, English (U.S.)

Formatted: No underline, Font color: Auto, English (U.K.)

Formatted: No underline, Font color: Auto, French (France)

Formatted: Font: Bold, No underline, Font color: Auto, French (France)

Formatted: No underline, Font color: Auto, French (France)

Formatted: French (France)

Formatted: No underline, Font color: Auto, French (France)



- 1  
2  
3  
4  
5  
6 13. Ministère de la Santé Publique du Cameroun. Directives nationales de prise en charge par  
7 les antirétroviraux des personnes (adultes et adolescents) infectés par le VIH. Yaoundé  
8 2007.  
9  
10 14. Wools-Kaloustian K, Kimaiyo S, Diero L et al. Viability and effectiveness of large-scale  
11 HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. *Aids*  
12 2006;**20**:41-48.  
13  
14 15. Biadgilign S, Reda AA, Digaffe T. Predictors of mortality among HIV infected patients  
15 taking antiretroviral treatment in Ethiopia: a retrospective cohort study. *AIDS Res Ther*  
16 2012;**9**:15.  
17  
18 16. Amuron B, Levin J, Birunghi Jet al. Mortality in an antiretroviral therapy programme in  
19 Jinja, south-east Uganda: a prospective cohort study. *AIDS Res Ther* 2011;**8**:39-  
20  
21 ~~17. MacPherson P, Moshabela M, Martinson N et al. Mortality and loss to follow-up among  
22 HAART initiators in rural South Africa. *Trans R Soc Trop Med Hyg* 2009, **103**:588-593.  
23  
24 ~~18. Yu JK, Chen SC, Wang KY et al. True outcomes for patients on antiretroviral therapy who  
25 are "lost to follow-up" in Malawi. *Bull World Health Organ* 2007;**85**:550-554.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60~~~~

Formatted: No underline, Font color: Auto, English (U.K.)

17. Ministry of Public Health, Republic of Cameroon. National AIDS Control Committee: Towards universal access to care and treatment for adults and children living with HIV/AIDS in Cameroon. Progress Report N° 4. 2006.
18. MacPherson P, Moshabela M, Martinson N et al. Mortality and loss to follow-up among HAART initiators in rural South Africa. *Trans R Soc Trop Med Hyg* 2009, **103**:588-593.
19. Yu JK, Chen SC, Wang KY et al. True outcomes for patients on antiretroviral therapy who are "lost to follow-up" in Malawi. *Bull World Health Organ* 2007;**85**:550-554.

Table 1 Demographic, clinical and biological profile of HIV patients started on antiretroviral therapy at the Yaounde Jamot Hospital in 2007 and 2008

Characteristics*	Overall	Men	Women	p-value
n	1444	617	827	
Median age, years (25 <sup>th</sup> -75 <sup>th</sup> percentile)	38 (31-45)	40 (34-47)	35 (30-43)	<0.0001
Residence, n (%)				0.98
Urban	1236 (85.6)	528 (85.6)	708 (85.6)	
Rural	208 (14.4)	89 (14.4)	119 (14.4)	
Tuberculosis, n (%)	428 (29.6)	214 (34.7)	214 (27.9)	0.0003
Weight, Kg				<0.0001
< 50, n (%)	308/1322 (23.3)	69/570 (12.1)	239/752 (31.8)	
50-60, n (%)	535/1322 (40.5)	204/570 (35.8)	331/752 (44.0)	
>60, n (%)	479/1322 (36.2)	297/570 (52.1)	182/752 (24.2)	
Median (25 <sup>th</sup> -75 <sup>th</sup> percentile)	57 (50 - 65)	61 (54-68)	54 (47.5-60)	<0.0001
WHO stage, n (%)				0.82
I and II	186/1295 (14.4)	78/553 (14.1)	108/742 (14.6)	
III and IV	1109/1295 (85.6)	475/553 (85.9)	634/742 (85.4)	
Platelets, X1000/mm <sup>3</sup>	244 (180- 320)	229 (173-309)	259 (190-330)	0.0005
Total lymphocytes, X10/mm <sup>3</sup>	130 (90-190)	130 (90-201)	130 (90-190)	0.88
CD4, /mm <sup>3</sup>				0.21
< 50, n (%)	468 (32.4)	216 (30.5)	256 (30.5)	
50-99, n (%)	257 (17.8)	111 (18.0)	142 (17.6)	
100-200, n (%)	562 (38.9)	231 (37.4)	331 (40.0)	
>200, n (%)	157 (10.9)	59 (9.6)	98 (11.8)	
Median (25 <sup>th</sup> -75 <sup>th</sup> percentile)	99 (36.2-161)	89 (33-155)	105 (39-166)	0.01802
Haemoglobin, g/dl,				<0.0001
< 8, n (%)	235/1388 (16.9)	67/594 (11.3)	168/794 (21.2)	
8-10, n (%)	506/1388 (36.5)	178/594 (30.0)	328/794 (41.3)	
>10, n (%)	647/1388 (46.6)	349 (58.7)	298 (37.5)	
Median, (25 <sup>th</sup> -75 <sup>th</sup> percentile)	9.9 (8.5-11.2)	10.5 (9-12)	9.5 (8.1-10.7)	<0.0001

NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; WHO, World Health Organisation

\* For all characteristics with missing values, estimates are based of the subset of participants with valid data for each relevant characteristic, and new denominators always provided.

- Formatted ... [1]
- Formatted ... [2]
- Formatted ... [3]
- Formatted ... [4]
- Formatted ... [5]
- Formatted ... [6]
- Formatted ... [7]
- Formatted ... [8]
- Formatted ... [9]
- Formatted ... [10]
- Formatted ... [11]
- Formatted ... [12]
- Formatted ... [13]
- Formatted ... [14]
- Formatted ... [15]
- Formatted ... [16]
- Formatted ... [17]
- Formatted ... [18]
- Formatted ... [19]
- Formatted ... [20]
- Formatted ... [21]
- Formatted ... [22]
- Formatted ... [23]
- Formatted ... [24]
- Formatted ... [25]
- Formatted ... [26]
- Formatted ... [27]
- Formatted ... [28]
- Formatted ... [29]
- Formatted ... [30]
- Formatted ... [31]
- Formatted ... [32]
- Formatted ... [33]
- Formatted ... [34]
- Formatted ... [35]
- Formatted ... [36]
- Formatted ... [37]
- Formatted ... [38]
- Formatted ... [39]
- Formatted ... [40]
- Formatted ... [41]
- Formatted ... [42]
- Formatted ... [43]
- Formatted ... [44]
- Formatted ... [45]
- Formatted ... [46]
- Formatted ... [47]
- Formatted ... [48]
- Formatted ... [49]
- Formatted ... [50]
- Formatted ... [51]
- Formatted ... [52]
- Formatted ... [53]
- Formatted ... [54]
- Formatted ... [55]
- Formatted ... [56]
- Formatted ... [57]
- Formatted ... [58]
- Formatted ... [59]
- Formatted ... [60]

Table 2 Determinants of all-cause mortality among HIV-positive patients started on antiretroviral therapy (n = 1444)

Variable	Age and sex adjusted		Multivariable adjusted	
	Hazard Ratio (95% CI)	p	Hazard Ratio (95% CI)	p
Age, per year	1.01 (0.98-1.03)	0.56	1.01 (0.99-1.03)	0.37
Male sex	1.44 (0.94-2.11)	0.10	2.15 (1.34-3.45)	0.002
Rural residency	1.14 (0.62-2.09)	0.68	-	
Active tuberculosis	1.59 (0.97-2.61)	0.07	2.35 (1.40-3.92)	0.002
WHO stage III-IV	4.57 (1.68-12.47)	0.004	3.63 (1.29-10.24)	0.02
Weight, per kg lower	1.04 (1.02-1.06)	0.0002	1.03 (1.01-1.05)	0.01
Platelet count, per 1000 lower	1.01 (0.99-1.03)	0.53	-	
CD4 count, per 10/mm <sup>3</sup> lower	1.06 (1.02-1.09)	0.003	1.04 (1.01-1.07)	0.02
Haemoglobin, per g/dl lower	1.14 (1.03-1.26)	0.02	1.12 (1.00-1.26)	0.05
AZT based regimens	0.91 (0.51-1.62)	0.76	-	

AZT, zidovudine; CI, confidence interval; WHO, World Health Organisation

Formatted: Indent: Left: 0", Hanging: 0.59"

Formatted: Font: 10 pt, No underline, Font color: Auto

Formatted: Font: 10 pt

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

For peer review only

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

6/6/2013 1:53:00 PM

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

For peer review only

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

For peer review only

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

6/6/2013 1:53:00 PM

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

For peer review only

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

For peer review only

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60



6/6/2013 1:53:00 PM

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

For peer review only

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

6/6/2013 1:53:00 PM

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

For peer review only

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

6/6/2013 1:53:00 PM

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

For peer review only

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

6/6/2013 1:53:00 PM

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

For peer review only

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



6/6/2013 1:53:00 PM

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

For peer review only

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

6/6/2013 1:53:00 PM

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

6/6/2013 1:53:00 PM

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1: Survival probability from Kaplan-Meier estimator (upper panel) and Weibull plot showing the cumulative distribution function for mortality during follow-up of patients with HIV infection who started antiretroviral treatment at the Yaounde Jamot Hospital in 2007 and 2008  
297x209mm (300 x 300 DPI)

Review only




Figure 2: Estimated cumulative distribution function for all-cause mortality by major subgroups among patients with HIV infection who started antiretroviral treatment at the Yaounde Jamot Hospital in 2007 and 2008  
297x209mm (300 x 300 DPI)

## STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Pages
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	4,5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4,5
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	4,5 / /
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	/ /
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5,6
Bias	9	Describe any efforts to address potential sources of bias	6,7
Study size	10	Explain how the study size was arrived at	4,5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6,7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding  (b) Describe any methods used to examine subgroups and interactions  (c) Explain how missing data were addressed  (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy  (e) Describe any sensitivity analyses	6  6 6 6  6

Continued on next page

**Results**

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	6,7
		(b) Give reasons for non-participation at each stage	/
		(c) Consider use of a flow diagram	/
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	6,7
		(b) Indicate number of participants with missing data for each variable of interest	13
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	7
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	7
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	/
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	14
		(b) Report category boundaries when continuous variables were categorized	/
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	/
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	/

**Discussion**

Key results	18	Summarise key results with reference to study objectives	8
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	9,10
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	8,9,10
Generalisability	21	Discuss the generalisability (external validity) of the study results	9

**Other information**

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	10
---------	----	---	----

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).